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Abstract
The strength of health systems predict access to medicines that prevent death from pregnancy
related complications (essential maternal health medicines). But little is known about the relative
impact of each health system building block on access. This quantitative cross-sectional study
applied Ishikawa model to examine the relative effect of health systems governance, facilities,
service delivery, financing and medicine procurement and distribution (independent variables),
on availability, affordability and accessibility (dependent variables) of maternal health medicines
in resource poor settings. Data analyzed was pulled from 37 WHO pharmaceutical country
profiles and USAID MCHIP survey that assessed national programs for the prevention and
management of Postpartum hemorrhage and Pre-Eclampsia/Eclampsia. Data analysis included
bivariate and multivariate logistic regressions. All independent variables, except for quality of
health services showed statistically significant association with access to maternal health
medicines and achieved a p-value < .05 in bivariate analysis. Only three predictors however
explained 27% of the variance (R2 =.266, F(5,162)=13.12, p<.01). The strength of medicine
procurement and distribution systems significantly predicted access to essential maternal health
medicines (β= -.41, p<.001), as did robustness of health system financing (β= -.51, p<.001), and
quality of health facilities (β= -.34, p<.05). Authorities may prioritize investments in quality
improvement, supply chain strengthening programs, and incentives for private sector financing
and public-private partnerships for health system strengthening. This study contributes to
positive social change by identifying key health system considerations that can inform future
efforts to close geographical gaps in MCH outcomes.
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Section 1: Foundation of Study and Literature Review

Introduction to the Study
Postpartum hemorrhage (PPH), pre-eclampsia and eclampsia are three leading causes of
death for women giving birth around the world. These conditions together account for nearly half
(41%) of the 289,000 pregnancy-related deaths worldwide (WHO, et al., 2014). They also
disproportionately affect women in developing countries (Say et al., 2014; WHO, 2014b).
Oxytocin, misoprostol and magnesium sulfate (herein referred to as essential maternal
health medicines) are three medicines that prevent and treat these pregnancy-related
complications. (Fujioka, & Smith, 2011). Yet, they are not readily available to women at urban
and rural hospitals or clinics in many locations where women give birth (USAID, Landscape
Analysis: Postpartum Hemorrhage Solutions, unpublished data, 2012).
Expanding access to essential maternal health medicines would lower maternal death
rates and improve maternal health (Wagstaff, 2004). In one study, USAID anticipated that if
oxytocin and misoprostol were available to all women giving birth, they would prevent 41
million postpartum hemorrhage cases and saved 1.4 million lives annually (USAID, Landscape
Analysis: Postpartum Hemorrhage Solutions, unpublished data, 2012).
In recognizing these realities, governments of many nations with support from
multilateral, bilateral and international non-governmental organization have developed and
implemented programs to improve access to essential maternal health medicines. But despites
these efforts, women in resource poor settings still lack adequate access to these medicines
(Spector, Reisman, Lipsitz, Desai, Gawande, 2013; Hill, 2012).
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Researchers attribute this to the vertical structure of these programs, and the shrinking
funding for public health witnessed in recent years (Paina and Peters, 2011). In other words,
components of the health system that affects access to essential maternal health medicines are
not adequately accounted for in programs to promote access to these medicines. This is either
because practitioners perceive medicines as a standalone component of a health system or
funding to promote access are not able to support implementation of multiple and competing
programs that facilitate access to these medicines (Paina and Peters, 2011).
To address these gaps, some studies have attempted to determine health system
facilitators and barriers to access to essential maternal health medicines. But these studies were
limited to single geographies, medicines or health system factor (Smith, 2011; Trans and Bero,
2015; Bigdeli et al., 2013). Therefore, little is known about the relative impact of each health
system factor on access to essential maternal health medicines, more so comparatively across
geographies in resources poor settings. There is a paucity of evidence on the factors that facilitate
or impede access to essential maternal health medicines in low and middle-income countries.
Health systems determinant of global access to essential maternal health medicines have not
sufficiently studies using nationally representative data.
In this study, I examined the relationship between health systems factors and access to
essential maternal health medicines to understand the relative impact of select health systems
factors on women’s access to these medicines in developing countries. This study is unique in
that it will focus on an under researched area of access to essential maternal health medicines.
Findings from this study will make an original contribution to understanding how
pregnant women’s interactions with the health system affect the use of maternal health medicines

3
in low and middle-income countries. For the first time, there will be empirical evidence on the
determinants of women’s access to essential maternal health medicines from a holistic
perspective.
Evidence generated through this research can contribute to efforts that aim to expand
access to essential maternal health medicines. New knowledge generated can be used to sensitize
policy makers and maternal health practitioners, regarding the potential effects of their decisions
and interventions respectively on various aspects of the health systems with regards to access to
maternal health medicines. The evidence can help policy makers and health managers in
international agencies and national governments to design relevant, timely and evidence
informed policies and programs to improve pregnant women’s access to maternal health lifesaving medicines and reduce the number of women dying from pregnancy related causes.
Finally, with multiple intervention options for improving women’s access to maternal
health medicines, and shrinking funding for public health programs, the information from this
study could guide selection of investment priorities and pint to areas of work that foster changes
in policy and practice and inform maternal health research and program priorities. These could
contribute to a reduction in global and national maternal mortality ratio – a positive social
change.
Main aspects of this section include a background that briefly summarizes the knowledge
gaps the study will attempt to fill, and why the study is important. This section also presents the
problem statement and purpose of the study. The nature of the study, research questions and
hypotheses are included alongside the theoretical framework to guide the study. I also present an
overview of recent literature related to the scope of the study including a review of the theories
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that form the basis of this study, and the methodological approaches explored in previous related
studies. I conclude this section with an explanation of what is known and controversial about the
variables of interest in this study, and what remains to be studied. Finally, assumptions, scope,
delimitations, limitations and significance of the study are highlighted
Problem Statement
Despite recent decrease in global maternal mortality ratio, approximately 830 women still
die every day because of complications during pregnancy or childbirth (WHO, 2015). The World
Health organization (WHO) estimated that by the end of 2015, roughly 303,000 women will
have died during and following pregnancy and childbirth (WHO, 2015). Postpartum hemorrhage
(PPH), pre-eclampsia and eclampsia are three leading causes of these deaths. In 2014, these
conditions, together accounted for nearly half (41 % of the 289,000 pregnancy related deaths that
occurred worldwide (WHO, et al., 2014). While postpartum hemorrhage (PPH) accounted for
more than two thirds of cases), hypertensive disorders (pre–eclampsia and eclampsia), sepsis,
and unsafe abortion accounted for the rest (Say et al., 2014).
These pregnancy-related complications and resulting maternal deaths are not distributed
evenly across the globe. Rather, an overwhelming 99% of maternal deaths occur in low income
countries, with over 50% reported in sub-Saharan Africa and almost one third in South Asia. In
2015 alone, the maternal mortality ratio in developing countries was 239 per 100 000 live births
versus 12 per 100 000 live births in developed countries (WHO, 2015). Also, the probability that
a 15–year–old woman will eventually die from a cause related to Postpartum hemorrhage (PPH),
pre-eclampsia and eclampsia is much higher for women living in low income countries than for
those who live in high income countries (1:180 vs 1: 4900). Furthermore, more than half of
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maternal deaths in Africa and Asia occur in fragile and humanitarian settings (WHO, 2015). In
countries designated as fragile states, the risk of dying from a cause related to Postpartum
hemorrhage (PPH), pre-eclampsia and eclampsia is 1 in 54; a consequence of breakdowns in
health systems (WHO, 2015).
The need for oxytocin, misoprostol, and magnesium sulfate (discussed in earlier section)
is therefore imminent. It is universal and present wherever deliveries occur: from urban hospitals
to rural clinics and homes where more than 50 percent of women in developing countries deliver
their babies (Montagu, Yamey, Visconti, Harding, & Yoong, 2011).
In other to make medicines universally available and accessible, the World Health
Assembly sanctioned the notion of essential medicines in 1975, and this has been followed by (1)
highlight in 2012 by the “United Nations Commission on Life-Saving Commodities for Women
and Children on the need to improve women’s and children’s health by increasing access to 13
high-quality, essential health supplies, including oxytocin, misoprostol, and magnesium sulfate”
- (Kade, & Moore, 2012; p.5). (2). Evidence– informed recommendations by the WHO that
highlight necessary interventions and medicines needed to improve the health of pregnant
women and prevent complications that occur during pregnancy and childbirth (WHO, 2011b;
WHO, 2012; WHO, 2013; WHO, 2012c).
Despite these high level championed efforts, recent data suggest that poor and vulnerable
women in Africa and Asia still lack adequate access essential maternal health medicines
(Spector, Reisman, Lipsitz, Desai, Gawande, 2013; Hill, 2012). Researchers attribute this to gaps
in the approach that characterize programs that aim to promote access to essential maternal
health medicines at country levels. According to the literature, the role of medicines is often

6
narrowed down to a health system input, so that approaches to improving access to medicines are
vertical and isolated rather than all-inclusive - considering other health system constraints that
hamper access to medicines (Paina and Peters, 2011; Bigdeli et al., 2013; p.2).
Access to maternal health services (such as essential maternal health medicines) has
important implications on maternal health and mortality. In other to improve access to essential
maternal health medicines, there is need to understand and incorporate the full spectrum of the
health system in research and practice regarding access to maternal health medicines (Paina and
Peters, 2011; Bigdeli et al., 2013; p.2; (Adam, Ahmad, Bigdeli, Ghaffar, & Røttingen, 2011).
Some studies have explored access to medicines, but not many consider component of the
health system in ways that are relevant to the unique characteristics of access to essential
maternal health medicines (Bigdeli et al., 2012). Many limit health system considerations to the
health sector. For instance, a recent survey of peer-reviewed publications on access to medicines
in low and middle-income countries demonstrated that only 27 out of 648 between 2003 and
2009 reported on broader pharmaceutical policies and reforms in low and middle-income
countries (Adam, Ahmad, Bigdeli, Ghaffar, & Røttingen, 2011).
These gaps in empirical evidence demonstrate the need for additional research on access
to maternal health medicines from a health systems perspective.
Purpose of Study
The purpose of the study was to determine the relative impact of health system factors on
access to essential maternal health medicines in low and middle-income countries. The study
measured the strength of association between each select health system factor and maternal
health medicines in low and middle-income countries. Health System factors prioritized in this
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study were identified based on finding from the literature and the knowledge gap on health
systems and access to maternal health medicines research.
Knowledge gained through this study could inform national and subnational level
maternal health policies and programs that have goals to make better the health of women in low
and middle-income countries. Finally, the study could inform the design of appropriate policies
that address specific health system factors that constrain women from accessing and using
essential maternal health medicines. In this era of declining resources for public health, National
and local level maternal health programs could use the evidence generated in this study to
identify health system factors limiting access to and use of maternal health medicines, and
prioritize programs based on their relative potentials to maximize impact.
Research Questions and Hypotheses
The Study had six research questions and corresponding hypotheses:
Is there a significant association between governance and access to essential maternal
health medicines in low and middle-income countries?
Ho1: there is no significant association between governance and access to essential
maternal health medicines in low and middle-income countries?
Ha1: there is a significant association between the governance and access to essential
maternal health medicines in low and middle-income countries?
Is there a significant association between pharmaceutical supply and access to essential
maternal health medicines in low and middle-income countries?
Ho2: there is no significant association between pharmaceutical supply and access to
essential maternal health medicines in low and middle-income countries?
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Ha2: there is a significant association between pharmaceutical supply and access to
essential maternal health medicines in low and middle-income countries?
Is there a significant association between the quality of health facility and access to
essential maternal health medicines in low and middle-income countries?
Ho3: there is no significant association between the quality of health facility and access
to essential maternal health medicines in low and middle-income countries?
Ha3: there is a significant association between the quality of health facility and access to
essential maternal health medicines in low and middle-income countries?
Is there a significant association between quality of service delivery and access to
essential maternal health medicines in low and middle-income countries?
Ho4: there is no significant association between quality of service delivery and access to
essential maternal health medicines in low and middle-income countries?
Ha4: there is a significant association between quality of service delivery and access to
essential maternal health medicines in low and middle-income countries?
Is there a significant relationship between health financing and access to essential
maternal health medicines in low and middle-income countries?
Ho5: there is no significant association between health financing and access to essential
maternal health medicines in low and middle-income countries?
Ha5: there is a significant association between health financing and access to essential
maternal health medicines in low and middle-income countries?
Theoretical Foundation of Study
Choice of theory. The Ishikawa diagram – an application theory of the complex adaptive
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system concept guided implementation of this study. Ishikawa diagram - also known as the
“fishbone” or “cause and effect” diagram was first developed by Kaoru Ishikawa in 1968 and has
been vastly utilized in the field of public health as well as the manufacturing industry (Ishikawa,
1968). The main goal of the Fishbone diagram is to illustrate in a graphical way, the relationship
between a given outcome and all the factors that influence this outcome, and provide additional
insight into the behavior of processes (Ishikawa, 1960).
In the 1960’s and 70s, the Ishikawa diagram was commonly used in the manufacturing
industry to design products, prevent quality defects, and identify potential factors causing an
effect or outcome. However, because of its characteristic flexibility and potential for wide
application, the fishbone diagram has been adapted to consider a variety of outcomes or effect
scenarios across multiple professions.
Recently, the diagram has been used extensively as theoretical framework for analysis in
the health care field – mostly as a continuous quality improvement tool to examine the causes of
a problem within a healthcare setting. For example, Hartwell and colleagues (2006) used the
fishbone diagram as an analytic approach to identify sources of medication errors in hospitals.
Maternal health researchers have also applied the Ishikawa framework to studies related
to access to essential maternal health medicines – the focus of this study. For example, in 2010,
Ridge et al. developed, used and proposed the use of this diagram to determine facilitators to the
availability and rational use of MgSO4 in Zambia. In 2013, Bigdeli et al. also used this diagram
in their study to highlight health system deterrents to access and use of MgSO4 in Pakistan. In
2015, Tran and Bero used the fishbone Ishikawa diagram that Ridge et al. developed to assess
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the barriers and facilitators to quality use of three essential medicines – oxytocin, ergometrine,
and MgSO4 in seven countries.
Rationale for choice of framework. It was anticipated that firstly, the Ishikawa diagram
would allow accounting for various factors that potentially predict access since this study aims to
predict patterns of access from various sources. The supply chain for pharmaceutical products,
especially in developing countries, are comprised of highly heterogeneous groups of actors (e.g.
many types of health care providers, managers, policy-makers, patients, regulators, private
sector, public sector etc.) intervening at multiple levels through a variety of services and
functions (Holland, 1992; Anderson and McDaniel, 2000; Plsek, and Wilson, 2001; Tan et al.,
2005; Rickles et al., 2007; Saadah & Knowles, 2000).; (de Savigny & Adam 2009); Keshavarz et
al., 2010). In other words, the medicine supply chain is woven and nested within the health
system and interacts with the peculiar behavior of different components of the health system at
any given time (de Savigny & Adam 2009). Medicines concern systems outside of the health
system and at international level.
Secondly, scaling up access to essential medicines for maternal health is more than the
expansion of coverage of health services. Rather, it can be defined as a set of processes that lead
to expanded and sustainable coverage of services, and should reflect the open and dynamic
relationship that exist in a health system (Anderson and McDaniel, 2000; Plsek, & Wilson,
2001). Scale up should also involve strengthening the capacity of delivery organizations,
increasing diversity and robustness of funding and management arrangements, and growing the
system's overall capabilities to add more services or to integrate services (Uvin 1995,
Subramanian et al., 2010; Tan et al., 2005; Leischow, & Milstein, 2006: Van Wave et al.,
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2010),). The Ishikawa diagram is structured to help explain processes that lead to a given
outcome and potential factors to promote scale up and improvement – hence it is suitable to this
study.
Logical Connection
In using the Ishikawa diagram to determine predictors of access to essential medicines for
maternal health, Tran and Bero (2015) proposed that facilitators and barriers to quality use of
oxytocin, ergometrine, and MgSO4 occur in four levels of a health system: (1).
Government/Regulatory level (2). Pharmaceutical Level (3). Health Facility Level (4) Health
professional Level.
In this cross-sectional study, I built on previous studies, like those of Tran and Bero
(2015). That applied the Ishikawa framework in maternal health medicines research. This
framework provided a solid platform for understanding relationship between the independent and
dependent variables for this study. I advanced this diagram through an iterative process that was
based on data gotten from each country’s report.

12

Figure 1. Ishikawa diagram showing the multi-dimensional predictors of rational use of oxytocin.
Source: Tran and Bero, (2015)

Nature of the Study
A quantitative cross-sectional approach was used to answer the research questions. This
approach is based on post positivist philosophical assumptions that propose: 1). examining the
relationships between and among variables is central to answering questions and hypotheses
through surveys and experiments; 2). reducing concepts to a parsimonious set of variables,
tightly controlled through design and statistical analysis, provides measures or observations for
testing a theory (Creswell, 2008). The research questions required quantitative analysis for
measuring access to maternal health medicines, and the associations between health systems
factors and access to maternal health services.
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I carried out a secondary analysis of archived data from a sample of Low and Middleincome Countries (LMIC). Key inclusion criteria were countries that participated in the second
USAID Bureau for Global Health's flagship Maternal and Child Health Integrated
Program (USAID/MCHIP) annual global survey between March to June 2012. These surveys
assessed progress of national programs in the prevention and management of PPH and PE/E
(USAID, MCHIP (2011, 2012).
The independent variables for this study were health-system characteristics that influence
women’s access to essential maternal health medicines. In this regard, five health system
domains was assessed: government and regulatory, pharmaceutical supply system, health
facility, and health service delivery, and data collection/information reporting. For each domain,
at least two health system characteristics or measures that best represent a domain were analyzed
(table 1.1).The outcome variable for this study was ‘access to essential maternal health
medicines’, defined as the availability, affordability and accessibility of Oxytocin, Magnesium
Sulfate and Misoprostol or Egometrin combined.
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Table 1
Health System Determinants of Access to Maternal Health Medicines
Variable Dimension

Measures

Government/regulation

Medicines approved at national level;
Availability of Standard Treatment Guidelines;
Policy provision for AMTSL present.
Written public sector procurement policy
available; Public sector procurement is
Centralized and decentralized? The
government supply system department has a
Central Medical Store at National Level; There
are national guidelines on Good Distribution
Practices (GDP)
Number of hospital beds per 10,000
Number of Physicians per 000 pop.
Pre-service education curricula include
AMTSL
Current global management principles for
PE/E included in in-service training courses

Pharmaceutical Supply and Distribution

Health Facilities and Infrastructures
Service Delivery

Health Financing

AMTSL included in in-service training
curricula
Pre-service education curricula include current
global management principles for PE/E
Students assessed for competency in
performance of AMTSL
Health providers aware medicine is first–line
treatment
Midwife/skilled birth attendants scope of
practice
Private health expenditure as % of total health
expenditure (% of total expenditure on health)
Pharmaceutical expenditure as a % of Health
Expenditure (% of total health expenditure)
Total health expenditure as % of Gross
Domestic Product

Note: These are the 6 health system characteristics identified as independent variables
for the study.
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Literature Search Strategy
Search Strategy
The literature review for this study was executed by searching for and reviewing peerreviewed and academic literature from computerized databases and resources available at
Walden Library: ABI/INFORM Global, Academic Search Premier, Encyclopedias from Sage,
eBrary e-book collections, Education Research Complete, Expanded Academic ASAP, General
Science Collection, Health and Medical Complete (ProQuest), Health Sciences: a Sage Full-Text
Collection, IEEE Xplore Digital Library, InfoSci Journals, Cumulative Index to Nursing and
Allied Health Literature (CINAHL), MEDLINE with Full Text ProQuest Central,
ResearchNow, Science Direct, SocINDEX with Full Text, and applicable academic textbooks.
Additional search focused on online databases like google scholar, WHO website,
UNICEF website, and those of other international non-governmental organizations that work on
access to medicines and health systems in developing countries. These organizations included
Management Sciences for Health (MSH), PATH, Population Service International (PSI), etc.
Reference lists of some retrieved articles were also reviewed.
Search Terms
The following keywords were used alone and in combination as search terms: health
systems, health care access, live-saving maternal health medicines, oxytocin, misoprostol,
magnesium sulfate, post-partum hemorrhage, eclampsia, pre-eclampsia, access, medicines,
pharmaceutical, essential medicines list. Only texts in English were reviewed, with most
literature published between 2003 and 2016.
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Scope of Literature Review
The literature review included (a) peer-reviewed studies, including systematic reviews
and meta-analysis; (b) studies that examined the association between maternal health medicines
or access to medicines more broadly with one or more health system determinants; (c) studies
published between 2005 and 2016; (d) studies published in English, and (e) studies published in
all regions.
Literature Related to Key Variables and/or Concepts
Global statistics on maternal health: Every day, approximately 830 women die because
of complications during pregnancy or childbirth (WHO, 2015). The WHO also estimated that by
the end of 2015, roughly 303 000 women will have died during and following pregnancy and
childbirth (WHO, 2015). An overwhelming 99% of these maternal deaths occur in low–resource
settings. For instance, in 2015 alone, the maternal mortality ratio in developing countries was
239 per 100 000 live births versus 12 per 100 000 live births in developed countries (WHO,
2015). Over 50% of deaths in developing countries occur in sub-Saharan Africa and almost one
third occur in South Asia. More than half of maternal deaths occur in fragile and humanitarian
settings (WHO, 2015).
Women in developing countries have on average, many more pregnancies than women in
developed countries. Consequently, their lifetime risk of death due to pregnancy and related
causes is higher (World Bank, 2012). For instance, the probability that a 15–year–old woman
will eventually die from a cause related to maternal health is much higher for women living in
low income countries than for those who live in high income countries (1:180 vs 1: 4900). In
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countries designated as fragile states, the risk is 1 in 54; a consequence of breakdowns in health
systems (WHO, 2015).
Advances on Maternal Health: In 2000, 189 member states of the United Nations adopted
eight Millennium Development Goals (MDG) (United Nations, 2000). The fifth MDG aimed to
reduce maternal mortality worldwide by 75% between 1990 and 2015 with an annual average of
5% (United Nations, 2000, United Nations, 2013). In sub-Saharan Africa, a number of countries
halved their levels of maternal mortality since 1990. In other regions, including Asia and North
Africa, even greater headway was made. Also, between 1990 and 2015, the global maternal
mortality ratio (i.e. the number of maternal deaths per 100 000 live births) declined by only 2.3%
per year. However, increased rates of accelerated decline in maternal mortality were observed
from 2000 onwards. In some countries, annual declines in maternal mortality between 2000-2010
were above 5.5%, the rate needed to achieve the MDGs. Despite a 43% decrease in maternal
mortality from 1990 - 2014, the annual rate of decline has been far below the MDG 5 target
(WHO, 2014; UN, 2013, 2015; Lozano et al., 2011).
However, seeing that it is possible to accelerate the decline, countries have now united
behind a new target to reduce maternal mortality even further. One target under Sustainable
Development Goal 3 is to reduce the global maternal mortality ratio to less than 70 per 100 000
births, with no country having a maternal mortality rate of more than twice the global average
(WHO, 2015).
The case for maternal health medicines: Most maternal deaths are preventable because
health-care solutions to prevent or manage complications are well known: access to antenatal
care in pregnancy, skilled care during childbirth, and care and support in the weeks after
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childbirth. It is particularly important that all births are attended by skilled health professionals,
because timely management and treatment can make the difference between life and death for
both the mother and the baby (WHO, 2015).
Based on these evidence, WHO provided recommendations for the essential interventions
and medicines needed to improve maternal health and prevent these maternal complications
[WHO, 2011b; WHO, 2012; WHO, 2013; WHO, 2012c). Oxytocin, misoprostol, and magnesium
sulfate—are medicines that prevent and treat these two leading causes of maternal death
worldwide: excessive bleeding after childbirth and high blood pressure during pregnancy.
Oxytocin is recommended to prevent and treat excessive bleeding (post-partum
hemorrhage) after childbirth. It is delivered through an injection. Misoprostol is recommended to
prevent and treat excessive bleeding after childbirth when oxytocin is not available. It comes in
tablets that are taken orally (Carroli, Cuesta, Abalos, & Gulmezoglu, (2008). Magnesium sulfate
is recommended for treating high-blood pressure (pre-eclampsia and eclampsia). It is
administered by an injection and needed at all levels of the health system where women seek
care (WHO, 2012).
The need for these three medicines are universal and present wherever deliveries occur:
from urban hospitals to rural clinics and homes, where more than 50 percent of women in
developing countries deliver their babies (Montagu, Yamey, Visconti, Harding, & Yoong, 2011).
But women who do not receive the necessary antenatal care miss the opportunity to detect
problems and receive appropriate care and treatment in the event of the pregnancy related
complications (WHO, 2015).
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While levels of antenatal care have increased in many parts of the world during the past
decade, poor women in remote areas are the least likely to receive adequate health care during
pregnancy and childbirth (WHO, 2015). This is especially true for regions with low numbers of
skilled health workers, such as sub-Saharan Africa and South Asia. For instance, only 51% of
women in low-income countries benefit from skilled care during childbirth and only 40% of all
pregnant women have the recommended antenatal care visits. This means that millions of births
are not assisted by a midwife, a doctor or a trained nurse. The high number of maternal deaths in
some areas of the world therefore reflects these inequities in access to health services, and
highlights the gap in the health system (WHO 2014). Expanding access to essential maternal
health medicines would lower maternal death rates and improve maternal health (Wagstaff,
2004).
Studies Related to Key Constructs and Methods
Oliveira et al (2002) carried out an implementation analysis to assess the success and
quality of implementation of programs on access to pharmaceutical care by people living with
HIV/AIDS in Brazil. Their approach focused on the process of producing outcomes and held
relationships as a central tenant of how a program interacts within their organizational context.
This approach allowed for continuous quality improvement because it takes into account the
dynamic nature of the system and considers relationships and linkages across several
components of the health system (Oliveira et al., 2002)
Logie and Harding (2005) used a multi-method approach to evaluate Uganda’s morphine
access program which handles chronic pain for cancer, HIV/AIDS and pain from sickle cell
crisis. The program was evaluated from three perspectives – legislative, clinical, and community.
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They used structured interviews, direct observation, and two sets of audits to capture the
complexity of pain care delivery system in Uganda. This three-pronged approach combined with
their consideration of the various aspects of the health system allowed Logie and colleagues to
explore the unintended outcomes of the drug policy in Uganda as well as process barriers faced
by various actors. It also allowed the authors to better predict the how the drug supply chain
could affect end users and how to improve on it (Logie &Harding, 2005).
Windisch et al (2011) used a mixed methods approach to explore the interaction within
and across various components of Uganda’s drug supply management systems. WHO’s health
systems framework for action that outlined seven health systems building blocks guided this
systematic study. The study applied the principle of ‘path dependence’ to consider initiating
conditions and the history of supply chain management in the country. Windisch et al (2011)
captured perspectives through key informant interviews, and laid out how the different pieces of
the system fits together, and how one part of the system affects the other. The authors also
showed feedback loops that pointed out unintended effects.
In 2012 also, Xiao, Zhao, Bishai, & Peters carried out a qualitative study in rural China.
Their study evaluated a national drug policy’s implementation for its intended outcomes and
unintended consequences. Xiao, et al., (2012) identified policy implementation actor involved
and their roles. In depth key informant interviews were used to understand the motivations of the
actors. They also considered the relationships and feedback loops created by the action and
responses of these actors to the policy and system. This study accounted for the systemic changes
caused by emerging patterns and activities by actors in a policy. A key finding from the study
was that policy and behavior of certain actors give rise to behavior patterns by other actors which
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in-turn give rise to self-organization, and a system that this is greater than the sum of its paths
Xiao, et al., (2012).
Another study in Iran looked at National Drug Authorities. In this study, Abdollahiasl et
al., (2014) built a system dynamics model to visualize the effects of market variables involving
the 5 P’s (Product, Price, Promotion, Place, People) on access, availability, affordability, quality
and rationality (Abdollahiasl et al., 2014). The authors also created a stock flow diagram that
allowed them to explore processes and evaluate policy approaches used to facilitate decision
making. Their model simulated what the system flow and outcome would be - including positive
and negative effects, with changes made at various levels of the system. Abdollahiasl and
colleagues also suggested that their model can be manipulated depending on what researchers
and policy makers would like to focus on as central concepts. For example, in this study, while
affordability and availability were the core of the model, quality and rationality were also tested
in terms of how they affect the system.
Camaroon et al., (2009) did an analysis of secondary data on medicine prices, availability
and affordability for 30 WHO essential medicines in 36 LMIC including some uteronics – which
was only reported for a handful of countries.
In 2010, Ridge et al. proposed the development and use of a fishbone diagram to rapidly
assess the barriers and facilitators to the availability and use of MgSO4 in Zambia. They used
this diagram as a conceptual framework to identify barriers and facilitators to the availability and
use of magnesium sulfate. However, this was a smaller scale case study at the facility level and
therefore did not explore factors across the health system based on interviews and focus groups.
It did however provide a strong basis for demonstrating complexity in translating research to
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practice, and it provided an effective way to understand barriers at the regulatory/government,
supply, procurement, distribution, health facility and health professional levels. Sevene, et al
(2005) did similar study in Mozambique and Zimbabwe where they reported on barriers to the
use of MgSO4 in these countries.
In their study to examine the inclusion of the priority medicines for maternal and child
health on national essential medicines lists, Hill, Yang and Bero, (2012) examined publically
available collection of the national essential medicines lists that have been submitted to WHO by
member states in the last 10 years (WHO, 2016). Only countries that had the most-up-to date list
in this time-frame were included in the study. Each EML was then evaluated for congruence with
WHO “list of priority medicines for Mothers and Children 2011(Hill, et al., 2012). HIV
medicines were excluded from the list because most countries have separate platforms for
purchasing HIV medicines. ‘Missing’ were also excluded because these formulations either do
not exist, or have not yet been fully commercialized. The authors compared specification of the
drug as the International Nonproprietary Name (INN), dosage form, and strength dose
combination of TB medicines is not available.
Smit et al. (2014) carried out a key informant survey in 37 LMIC to identify both national
and global gaps in PPH and PE/E program priorities and to highlight focus areas for future
national and global programming. The survey looked at the three essential maternal health
medicines of interest in this study, and consisted of a 44-item questionnaire that addressed 6 core
programmatic areas: policy, training, medication distribution and logistics, national reporting of
key maternal health indicators, programming, and challenges to and opportunities for scale up.
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An interesting aspect of Smit et al. (2014) study is the inclusion of certain programming
indicators that could serve as objective pointers to access and use of these medicines in LMIC.
Bigdeli et al (2013) used mixed methods including policy document review, key
informant interviews, focus group discussions and direct observation at health facility to explore
use of magnesium sulfate for sever pre-eclampsia and eclampsia in Pakistan. They used a fish
diagram to identify causal pathways and in the process highlighted barriers and enablers of
access to magnesium sulfate. Their study considered the following levels of health system individual, households and communities; health service delivery; health sector; national level
beyond the health sector and international level. They conducted interviews and focus groups to
capture the multitude of factors and actors at play in preventing or facilitating access to and
appropriate use of magnesium sulfate; and to provide further interpretation of the fish diagrams
nodes. Context specific health system barriers and enablers were identified and their capacity to
affect access and use of magnesium sulfate was used to make policy recommendation.
A major strength of their study was the triangulation of data sources and methods of
collection – as it allowed for more comprehensive exploration of the different levels of the health
systems as well as the various building blocks of the health system. Context specificity is also an
important strength of this study in improving availability and use of medicines within the service
delivery system used to map determinants of access to and use of life saving maternal health
medicines at all five levels: health sector and health service delivery levels.
Tran and Bero (2015) analyzed seven UNFPA/WHO reports published in 2008–2010.
These reports summarized country–wide rapid assessments of access to and use of essential
medicines for maternal health in Mongolia, Nepal, Laos, the Democratic People’s Republic of
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Korea (DPRK), the Philippines, Vanuatu, and the Solomon Islands. Tans and Bero used a
“fishbone” (Ishikawa) diagram as the analytic framework to identify facilitators and barriers at
four health–system levels: government/regulatory, pharmaceutical supply, health facility, and
health professional.
Something of note is that the majority of these studies that explore access to uteronics
used similar methodology, constructs and variables in their research. For instance, Smith et al.,
(2011) administered a 44-item survey addressing 6 core programmatic areas: policy, training,
medication distribution and logistics, national reporting of key indicators, programming, and
challenges to and opportunities for scale-up. Trans and Baro (2015) explored the following
measures for oxytocin, Ergometrine and magnesium sulfate in their study: (1) need and demand,
(2) availability, (3) presence on essential medicine lists, (4) inclusion in standard treatment guide
lines and protocols, (5) rational use, (6) licensing and areas of quality assurance, (7) storage, (8)
procurement and supply chain, (9) costs, and (10) coordination and integration between public
and private collaboration efforts. A couple other studies (Tran and Bero, 2015, Ridge et al.,
(2010). Bigdeli et al., 2009; SeveneSevene, et al., 2005) considered health systems barriers and
facilitators to access to one or a combination of maternal health medicines in LMIC.
Health Systems and Access to Medicines
Defining health systems: The WHO defines a health system as a system "whose primary
purpose is to promote, restore, or maintain health" (WHO, 2000). According to WHO (2000),
health system activities range from direct service provision through clinics and hospitals to
community level prevention strategies and health education.
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In other to ensure stakeholders have a shared understanding of what health systems are
and actionable points for strengthening health systems, WHO developed a framework comprised
of six building blocks of a health system: 1) health service coverage, 2) human health resources,
3) health information systems, 4) medical products, vaccines and technology, 5) health financing,
and 6) leadership and governance (WHO, 2007). These building blocks are expected to support a
“health system that can prevent, treat and manage illness and to preserve mental and physical
well-being for all individuals equitably and efficiently, within a specified geographic area”
(WHO, 2007, p. 2).
Defining and Measuring Access: Although the concept of access - broadly is commonly
thought to be quite complex, researchers have explored the concept in health care since the
1970’s, and have put forward a myriad of definitions (Srivastava, 2011; Donabedian 1972; Aday
& Andersen, 1974; Penchansky, 1977; Gulliford, Figueroa-Munoz, et al. 2002; Oliver &
Mossialos, 2004). In terms of measuring access, the literature does not present a clearly defined
pattern for measuring access since multiple factors affect access to medicines including health
facilities, service providers, money, knowledge and beliefs (Hausmann-Muela, 2003). However,
it is common to find access being measured based on dimensions suggested in ‘access’
definitions and according to the particular access topic being investigated e.g. health care,
medicines, etc.
Service utilization - Donabedian (1972) defined proof of access to be the use of service
rather than whether the facility exists – as suggested by other researchers. He also proposed that
access should be distinguished between two components: initiation and continuation

26
(Donabedian 1972) Aday and Anderson’s (1974) point that the potential to utilize was distinct
from utilizing a service or gaining access appear to align with Donabedian’s (1972) assertion.
Similarly, Wagstaff & van Doorslaer, (2000) defined access as the utilization of health
services or treatment. According to them, utilization of health services did not depend on the
availability of treatment opportunities alone, but includes the extent to which individuals avail
themselves of the opportunities (Wagstaff & van Doorslaer, 2000a).
Interaction between individuals and a health system - Other researchers like
Penchansky (1977), Mooney (1983), Oliver and Mossialos (2004) thought that access should not
be only construed as utilization of health services, but should include the interaction between an
individual and the health system. Access should also demonstrate a sync between demand and
supply related factors (Donabedian 1972; Penchansky 1977; Gulliford et el., 2002; Oliver and
Mossialos, 2004). It should relate to factors beyond time and monetary cost of seeking care (Le
& 1982; Mooney,1983), but extends to include income (Olsen, & Rogers, 1991), services,
quality, personal inconvenience, cost and information (Goddard & Smith, 2001).
Accordingly, in 2002, Gulliford et al proposed the following dimensions as measures of
access: Availability of Health service - which focuses on the supply and utilization of health
services; Health service outcomes which depicts how relevant, effective and quality services are;
Equity of access - which relates to the extent to which people access services in proportion to
their needs.
Some researchers like Palmer (2008) have also proposed simpler measures like equality
of expenditure (the extent to which monies spent on people are the same) or equality of
utilization (the extent to which people equally use a health facility).
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Similarly, Thiede et al. (2007) defined access more broadly as “freedom to use health
services” (Thiede et al., 2007, p. 105). Their definition considered three dimensions: availability;
affordability, and acceptability of health services. In their view, availability refers to the extent to
which needed services are available, within geographical reach and equitably distributed across
different population groups. Affordability refers to the financial access in the broadest sense (e.g.
direct costs, indirect costs, household financial wealth). In this regard, other researchers have
advocated for measures like use of health care, Out- of-Pocket (OOP) payments for health
services, health status, mortality, or funding allocated from governments (Brockerhoff and
Hewett, 2000; Dayton et al. 2000; Makinen, Waters, et al. 2000; Wagstaff, 2000b). Acceptability
refers to how patients perceive health services including health worker attitude to patients,
cultural attitudes of patients towards health care services, condition of premises, waiting times,
duration of consultations, and quality of care in public versus private facilities.
Access to Pharmaceuticals: Some researchers have used models of health services
utilization to define access to pharmaceutical products because access to medicines is considered
to be a subset of health services utilization (e.g., Kloos et al., 1986; Miralles and Kimberlin,
1998). However, a couple of disadvantages exist with strictly using “utilization” to describe
access (Aday & Andersen, 1981). Firstly, utilization does not capture all aspects of access. For
instance, the difference between health service utilization and access to medicines is quite
distinct: unlike health service utilization, both pharmaceutical products and pharmaceutical
services impacts access to medicines. So defining access strictly by service utilization leaves out
the opportunity to understand the role of pharmaceutical product characteristics in determining
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access. It also does not reflect individuals who need health care but do not receive it (Aday &
Andersen, 1981).
Furthermore, utilizations may identify equity challenges in the distribution of health care
services but it may not fully capture the appropriate level of quantity or quality of care (Thiede et
al. 2007). For instance, the utilization pattern may be skewed towards lower income groups but
this may be because the alternatives for the poorer segments of the population are unaffordable
(Thiede et al. 2007). Consequently, access to medicines needs to be considered in terms of the
service as well as the goods that are delivered by the service.
In addition, Kloos et al., (1986) noted that when defining access to pharmaceutical
products and services, it is important that definitions of access to pharmaceutical commodities
extend beyond explaining utilization by “entry use” through a prescription from a health care
professional to incorporate utilization patterns in the informal sector and in self-medication
(Miralles and Kimberlin, 1998). This is because many drugs are available to the general public in
a relatively uncontrolled environment. For most medicines, consumers are allowed greater
leeway in personal decision making about drug use than are patients seeking care in treatment
facilities (Kloos et al., 1986).
Furthermore, the issue of ‘pharmaceutical integrity and bioequivalence of the product as
well as the quality of the services that affect the appropriate use of the product’ comes to play in
defining access to pharmaceuticals. In this regard, Miralles and Kimberlin, (1998) suggested that
considerations for access to pharmaceutical products should incorporate access to information
needed to make appropriate decisions regarding availability and use of the product. Information
in this context include all aspects of drug supply chain including selection, procurement,
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distribution and use. They should also address concern regarding the continuity or sustainability
of access to pharmaceutical products and services, especially for use in chronic or endemic
situations.
Determinants of Access to Medicines
In this section, we discuss the literature regarding determinants of access to medicines
from two dimensions that appear to be common themes - theoretical propositions and empirical
research findings. These represent rationale for selection of variables proposed for this study.
Multiple Conceptual Propositions that attempt to explain factors that determine access to
medicines are discussed in following paragraphs.
WHO-MSH 2000 framework: WHO-MSH 2000’ ATM framework was the first
‘Access to Medicines’ (ATM) framework that attempted to define how access to medicine
should be measured from a health systems perspective. It was developed in 2000 during a WHOMSH consultative meeting in Ferney–Voltaire (Centre for Pharmaceutical Management, 2003).
This framework was informed at the time by 1) WHO Medicines Strategy: Framework for
Action in Essential Drugs and Medicines Policy, 2000–2003 (WHO, 2000), 2) Country
experiences with using existing pharmaceutical sector indicators, and 3). Penchansky and
Thomas’s (1981) 4As of access framework: ‘Availability’, ‘Accessibility(geographical)’,
‘Acceptability’ and ‘Affordability’, with ‘Quality’ of products and services as a cross-cutting
determinant – which also represents the dimensions for WHO-MSH framework. Also, each of
the A’s had two demand and supply focused indicators.
The WHO 2004 ‘Equitable Access Framework: The WHO 2004 ‘Equitable access to
essential medicines’ framework was the next major access to medicine model that evolved. This
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framework was developed because there was global recognition that in the last two decades prior
to this time, tremendous progress had been made in ensuring access to medicines globally, but
significant equity gaps remained (WHO, 2004).
Not everyone had benefited equitably from global improvements in the provision of less
costly and more effective treatments with essential medicines. The WHO (2004) model proposed
that four dimensions of a system predicts access to medicines - 1) Rational selection and use,
‘Affordable prices’, Sustainable financing, ‘Reliable health and supply system.
Rational selection emphasize the need to rationalize medicine choices (WHO, 2004). In
other words, countries needed to identify, give preference and promote access to those medicines
that will have the greatest impact in a given health care setting – This concept was later referred
to as essential medicines list (WHO, 2007). ‘Rational use’ proposes to improve use of medicines
by consumers. That is, to ensure safe and effective treatments, and minimize the risks and waste
linked to irrational prescribing and use of medicines through trained medical personnel’s and
adequate diagnostic equipment’s. ‘Affordable prices’ relates to supply-side aspect of
affordability.
‘Sustainable financing’ is viewed in the context of overall health care financing, and
addresses resource mobilization and pooling (public funding, donor assistance and development
loans, donor funding for and donations of medicines), and reduction of out-of-pocket and
catastrophic expenditures. The ‘reliable health and supply system’ dimension of the WHO -2004
framework assume that among the many elements of an effective health and supply system, four
elements are most important in supporting access to essential medicines are: Health sector
development (human resources for health, health equipment’s, hospitals, etc.), public-private-
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NGO mix, regulatory control, procurement co-operatives, and Traditional and complementary
medicines.
Frost and Rich framework: Frost and Reich (2010) examined how poor people in poor
countries access health technologies, including medicines. In their model, they adopted a 4A
framework for ATM - though different from the WHO-MSH 4A model (Table 1.2):
‘Architecture’, ‘Availability’, ‘Affordability’ and ‘Adoption’ are the determinants of access. In
their framework, ‘Availability’ represents supply and includes manufacturing, forecasting,
procurement, distribution and delivery functions. ‘Adoption’ represents demand at all levels.
‘Affordability’ integrates costs, at government, non-government and end-user levels. All three
are coordinated by organizational relationships at national and international levels, represented in
the pharmaceutical ‘Architecture’ function.
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Table 2
Domains and Determinants Covered in Existing Frameworks for ATM
ATM
Framework

Domains

WHO-MSH
Availability
2000 (Centre
for
Affordability
Pharmaceutical
Management,
Acceptability
2003)

WHO (2004c

Specific Dimensions

Crosscutting
Determinants
of
Medicines’ supply—type and quantity, Quality
products and
Medicines’ demand—type and quantity
services
Prices of drug products and services,
User’s income and ability to pay
Prices of drug products and services,
User’s income and ability to pay,
Characteristics of products and services
User’s attitudes, expectations of products
and service

Accessibility

Medicines’ supply location, User location

Rational Use

Rational therapeutic choices, Improved
medicines’ use by consumers

Affordable Prices

Medicines’ pricing policies,

Quality of
medicines

Sustainable Financing

Resource
mobilization,
Pooling,
Reduction of out-of-pocket expenditures,
Reliable health and supply systems
Reliable Health and Medicines procurement and supply,
Supply Systems
Regulation, Human resources
Frost and Reich Availability
Manufacturing,
Forecasting,
(2010)
Procurement, Distribution, Delivery
Affordability
Government
affordability,
Nongovernmental agency, affordability, Enduser affordability
Adoption
Global adoption, National adoption,
Provider adoption, End-user adoption and
appropriate use
Individual,
household,
Perceived quality of medicines and health
Bigdeli et al’
Community
services, Cost of medicines and services,
2013
irrational
health-seeking
behavior,
demand for and use of medicines, Social

Architecture:
organization
relationships
at national
and
international
level
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Health service delivery

Health Sector

and cultural barriers (stigma related to
poverty, ethnicity, and gender)
Irregular availability, High medicine
prices
Irrational prescription and
dispensing, Low quality/sub-standard and
counterfeit medicines, Low quality of
health services, Competition between
public and private health service delivery
Pharmaceutical
sector
governance,
Medicines price control,
Weak health sector governance affecting
all health system

building blocks, Health sector pluralism
and stewardship over private sector
Public Policies Cutting Low
public
accountability
and
Across Sectors
transparency, Low priority attached to
social sectors
High burden of government bureaucracy
Conflict between trade and economic
goals for pharmaceutical
markets and public health goals
International
and Unethical use of patents and intellectual
Regional Levels
property rights, International donors’
agenda,
Distorted
research
and
development, not targeting disease
burden in LMICs
Source : Bigdelo et al., (2013)
Bigdeli framework: In 2013, Bigdeli et al developed an ‘access to medicines from a
health systems perspective’ model. This model was proposed as a paradigm shift from traditional
access to medicines frameworks (discussed further latter in this chapter) which only partially
addressed the full range of ‘access to medicines’ predictors. It is intended to promote a systems
approach to improving access to medicines, to ensure that policies are more effective and
generate longer-term equitable and sustainable results.
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This 2013 framework proposed that different elements of a health system predict access
to medicines: Characteristics of individuals, households and communities; resources, service
delivery, and governance (Bigdeli et al., 2013). These elements interact with each other in
multiple and dynamic ways, are supply and demand- driven, and occur at different levels: (1)
individual, households and community level; (2) health service delivery level; (3) health sector
level; (4) national level beyond the health sector (public policies cutting across sectors) and (5)
international/regional levels (Bigdeli et al., 2013). Some authors categorize the ‘individual,
households and communities’ elements as demand -side determinants, and resources, service
delivery, and governance as supply side determinants (Ensor and Cooper 2004; Peters et al.
2008; Jacobs et al. 2012).
Bigdeli et al (2013) framework was based on recognition that previous models
emphasized more of supply-side approaches to address demand-side constraints. Previous
models also tended to focus more on products than service delivery. Except for the WHO-MSH
(2000) model – which seems to be clearly centered on health service delivery, and the WHO
health systems framework – which was more encompassing, all others centered on the
medicines/medical products (Bigdeli et al., 2013). Bigdeli and colleagues also noted that
governance in all three models focused on the pharmaceutical sector, and there are minimal
linkages with national policies beyond the health sector. Their model considers equally, both
supply and demand-side approaches, as well as products and services from both pharmaceutical
and non-pharmaceutical perspectives. Their model also incorporates ATM predictors from both
the health sector and non-health sector and advocates for approaches that weaves ATM into other
aspects of a health system.
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Findings from Past Research
Socio-economic and demographic determinants: Different measures of equity and
economic status have been considered as predictors of access in developing country settings
(Wagstaff 2000b), Wagstaff (2000b) and colleagues looked at the population according to
subgroups like wealth quintiles (Wagstaff, 2000b), gender and ethnicity (Brockerhooff &
Hewett, 2000), health condition (Gakidou, Murray, et al., 2000) geographical location, age,
education or occupation (Gwatkin, 2000b). Household consumption, expenditure, or asset
ownership, are also common proxies used in the literature, and are considered better measures in
these settings. Income data are not considered reliable measures because there can be underreporting. They can also be seasonally dependent and do not necessarily capture longer-term
income or permanent wealth in low -income settings (Makinen et al. 2000; Palmer 2008).
Social status is also commonly considered as predictors of access and education and
occupation are more commonly used as proxies for social status. For example, data sets from the
Demographic and Health Surveys allow analysis of household assets by creating an asset index
and the application of principal component analysis (Filmer, & Pritchett, 2001).
Heller (1982) and Dzator et al. (2004) also looked at distance and time as predictors of
access. While distance is typically modelled as distance from health facility, time related
information is analyzed as time spent traveling to the health facility, waiting time and treatment
time. For example, Heller (1982) found that a 1% increase in waiting time will affect the
probability of demand by -0.02% to 0.02%. Dzator et al. (2004) found that a 1% increase in
distance will reduce the probability of demand for treatment by -0.36% at a public provider.
However, a limitation with findings related to time and distance is that most studies use
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aggregate level data rather than household level (Srivastava, 2011). It may be worth noting that
the “time’ indicator has also been used as indicator for health service delivery.
Health systems determinants: While systemic determinants may include a variety of
factors, the literature regarding access to medicines and uteronic appear to be heavy on a few.
The robustness of a public health system has been highlighted as a necessary component to
achieve the Millennium Development Goals (MDG) (Farahani, Subramanian & Canning, 2009;
Freedman et al, 2005). Hoppu, Ranganathan, & Dodoo, 2011; Oshikoya, and Senbanjo, (2010) in
summary noted that reasons for the lack of essential medicines include fragile supply systems,
out-of-pocket payments which make the medicines unaffordable, and poor quality products.
Additionally, Ridge et al.(2010) identified the following requirements (or critical
components) for adequate access to and use of MgSO4 in their Fishbone Diagram: inclusion of
MgSO4 in National Essential Medicines List (NEML) and Standard Treatment Guidelines
(STG), registration in the country for use in treatment of severe pre-eclampsia and eclampsia,
presence of a suitable procurement and distribution system, presence of a suitable local protocol
for use by health facilities providing basic and emergency obstetric care, awareness and adequate
training of health professionals on the use of MgSO4 as first line treatment for severe preeclampsia and eclampsia, availability of supplies and equipment to administer MgSO4 at facility
level. These are discussed in greater details in following sections.
Leadership, governance and policies - Muldoon et al (2011) found that the more
corrupt a government is perceived to be (i.e. lower CPI score) the stronger the association with
increased rates of infant, child and maternal mortality. As health systems are publicly
administered and require strong national commitment and resources, a corrupt government runs
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the risk of diverting public health resources for private gains (Pinzón-Flórez, et al., 2015).
Corruption is also found to be an indication of “The establishment, application, and follow-up of
rules for the health system; the extent to which there is equality of conditions for all the agents of
the system; and, the definition of the strategic agents for the health system as a whole.” (PinzónFlórez, et al., 2015).
National policies were also identified as critical predictors of access to uteronics – the
most popular being the presence of uteronic in global and national essential medicines list. Smith
et al., (2014) found that countries that reported infrequent availability of misoprostol noted a lack
of a national policy supporting misoprostol as a principle cause. Similarly, Tran & Bero, (2015)
found that the first common facilitator of quality use of oxyttocine egometrin and magnesium
sulfate at the government policy level was that all three essential medicines were consistently
listed on national EMLs.
Ridge et al. (2010) also identified inclusion of MgSO4 in National Essential Medicines
List (NEML) and Standard Treatment Guidelines (STG), as precursor to adequate access to and
use of MgSO4. Bigdeli, Zafar, Assad, & Ghaffar, (2013) found that lack of adequate translation
of national policies into implementation arrangements was an important determinant of access to
and use of MgSO4. They are related to fragmentation of procurement and supply based on
demand from practitioners rather than on NEML or national policies Bigdeli, Zafar, Assad, &
Ghaffar, (2013).
Pharmaceutical supply system and market dynamics - Reasons for the lack of
essential medicines include fragile supply systems (Hoppu, Ranganathan, & Dodoo, 2011;
Oshikoya, & Senbanjo, 2010), (Hill, Yang & Bero, 2012) thought that essential medicines should

38
be manufactured according to quality standards, licensed for use by regulatory authorities, on
essential medicines lists, part of national standard treatment guidelines, procured from the
supplier of a quality product, in the supply chain, and prescribed by health care professionals
who know how to use them (Hill, Yang & Bero, 2012).
In Zambia, the major barrier to availability within the public health system was lack of
procurement by the Ministry of Health (Ridge, Bero, & Hill, 2010), (Javadi & Bigdeli, n.d)
thought that information systems can also play a critical role in drug supply management and
avoidance of stock-Outs - a central tenet to poor access.
Sevene et al., (2005) identified a range of market and system failures that explained the
use of MgSO4 in Mozambique and Zimbabwe: these include the low price of generic MgSO4
which is a deterrent to effective marketing practices by pharmaceutical companies and a lack of
specific public intervention to correct the situation. Accordingly, Bigdeli, Zafar, Assad, &
Ghaffar, (2013) found that De-facto monopoly of a single pharmaceutical company and a small
market creates disincentive for marketing MgSO4.
Poor availability of magnesium sulfate may also reflect limitations of procurement
systems. In one study, magnesium sulfate was not supplied to the lower levels of care because it
was out of stock at the Central Medical Store (Ridge, Bero, & Hill, 2010). Affordable price of
MgSO4 was added as a requirement.
Quality of product and services - In 1993, McPake noted that quality is a difficult factor
to capture in both cross-section and time series analysis, and this theme seem to be widely
allured to in the literature. This is because quality as a variable has multiple dimensions – such as
availability, affordability, health human resources, and health service delivery. These dimensions
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also happen to be used in other themes regarding access - either as standalone indicators of
access and use of medicines or as determinants of access. Quality cuts across multiple levels of
the health system including health service delivery, human resources, trainings, and products.
As a result, most quality and access studies are unable to capture some important
dimensions of quality such as process and outcome (Sepehri and Chernomas 2001). They are
also unable to control for the marginal influence of covariates. For example, drug availability – a
widely used measure of quality in access to medicines is an important factor for patients but this
measure is influenced by both demand and supply factors (Sepehri and Chernomas 2001).
That said, studies on quality for access have produced mixed results of its effect on
utilization. While some studies suggest that perceived quality of care is an important predictor of
health care utilization and success of health system financing reforms (Annis 1981; Wouters
1991; Barnum H and Kutzin J 1993; Lavy and Quigley 1993), others suggest otherwise. For
instance, Bitran (1989) and Yoder (1989) found that utilization was lower where quality of care
was perceived to be lower. Hutton (2004) and James et al. (2006) also had similar findings utilization in smaller phased-in programs increased when combined with quality improvements.
Chalker (1995) found that an increase in drug availability led to increases in utilization
after an initial drop due to the introduction of user fees. However, Deolalikar (1998) noted a
couple of years later that even though drug availability provides useful information, it only
captures one relevant aspect when used in and of itself, and cannot account for whether it would
imply better treatment.
Wouters (1991) report of Denton, et al. (1990) and Akin, et al (1990) findings also
indicated that in a region of Nigeria three aspects of quality were significantly associated with
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utilization: percentages of years’ drugs are available, operational cost per capita, and facility
condition.
In contrast, Annis (1981) found that rural health posts had reasonable good quality of
services but were not used. Denton, et al. (1990) and Akin, et al (1990) findings also indicated
that machinery (x-ray machine and laboratories), number of support personnel, nurses and
doctors per capita were not significant as well. In the same studies, investment in quality
improvements were not offset by the revenue generation from user fees (Denton et al., 1990).
Service delivery affects how medicines can reach patients and the extent to which
rational use of medicines are upheld and promoted (Rouse, 2008; Javadi, and Bigdeli, (n.d).
Well- trained human resources are required for improved diagnoses, prescribing and dispensing
practices as well as for supporting adherence to drug regimens where home - based care is
necessary.
Also, a measure of quality as the probability of being seen by a physician was
insignificant (Heller 1982; Mwabu, Ainsworth M et al. 1993). In the same vein, Muldoon et al
(2011) used an amalgamated measure (i.e. nurses, doctors, skilled birth attendants) for human
health resources and found that physician density, and health financing as measured by less outof-pocket payments were associated with decreased mortality for infants and children. Ridge, et
al., (2010) also found that a lack of in-service training in the use of a specific medication was a
barrier to access to that medication.
Ridge et al (2010) identified access to antenatal care services as a requirement for access
to and use of MgSO4. They also noted that lack of demand by health professionals at the health
center level negatively affected access to MgSO4. Bigdeli, Zafar, Assad, & Ghaffar, (2013)
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found that lack of adequate translation of national policies into implementation arrangements
was an important determinant of access to and use of MgSO4. They are related to fragmentation
of procurement and supply based on demand from practitioners rather than on NEML or national
policies.
Ridge, Bero, & Hill, (2010) noted that persisting practices of using diazepam or
immediate referral without stabilization also acted as bottlenecks to access of MgSO4. In their
study, there were no local protocols nor referral guidelines, and therefore little support for health
staff to use MgSO4. However, the fact that drugs are produced locally served as an enabler to
access because the country is able to navigate the challenge of international issues, and price is
lower, hence affordable.
Another enabler based on finding from Ridge, and colleague’s study (2010) is that
procurement was based on NEML, and health professionals were trained to administer and
diagnose pre-eclampsia, and eclampsia. The fact that Magnesium sulphate was not supplied to
the lower levels of care because it was out of stock at the Central Medical Store, served as a
deterrent (Ridge, Bero, & Hill, 2010).
Haddad and Fournier (1995) found that in a rural setting in Zaire, a steady supply of
drugs did not reverse a reduction in utilization, the competence of health care professionals, and
the improvements in infrastructure and machinery. These findings were similar to those of
Mwabu (1993) who found that greater availability of medicines had a negative relationship on
utilization. But, Ridge et al. identified access to antenatal care services as a requirement for
access to and use of maternal health medicines. They also noted that lack of demand by health
professionals at the health center level negatively affected access to these medicines.
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Health and pharmaceutical financing - Financing systems are a major bottleneck to
access due to low affordability of drugs; without national policies to give universal access to
essential medicines, those living below the poverty threshold are unlikely to access medicines
when necessary (Javadi & Bigdeli, (n.d). Leadership and governance play an important role in
preventing corruption and sale of drugs in black markets; regulation also serves to mitigate
problems of counterfeits and substandard medicines (Javadi & Bigdeli, (n.d).
A limitation with studies that considered quality is that most of them were small scale,
had short time horizons and lacked robust methods and design (e.g. randomized) (Srivastava,
2011). According to Srivastava, (2011) for most studies, findings were based on observation
rather than modelling. As a result, it is difficult to properly assess the impact of quality on
utilization.
Review and Synthesis of Studies Related to Key Independent and Dependent Variables
Many LMIC have elements in place to ensure access to essential maternal health
medicines for addressing PPH and PE/E, but notable gaps remain in both policy and practice
(smith et al., 2014). In this section, some of these as featured in the literature are presented. The
availability of functional drug registration systems and manufacturing practices, and licensing
status are also considered.
Medicines in Essential Medicines List: In 2007, WHO found that 131 of 151 countries
surveyed had an essential medicines list (Hill, Yang & Bero, 2012). Twenty-four of the national
essential medicine lists were last updated prior to 2007. There was one list from 1999; but all
others prior to 2007 were from 2001 to 2007. The four priority medicines most recently added to
the WHO Model Essential Medicines List were misoprostol, cefixime, nifedipine, and zinc, all
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added in 2006. The more up to date lists were more likely to contain the four medicines added in
2006 than the older lists (Hill, et al., 2012).
Hill, et al., 2012) found considerable global variation in the listing of Priority Medicines
for Mothers on national essential medicines list. Their findings demonstrated that for prevention
and treatment of postpartum hemorrhage in women, oxytocin was more prevalent on the lists
than misoprostol - included on 55 (62%) and 31 (35%) of lists, respectively – although
misoprostol was more likely to be listed on country essential medicines lists in the WPRO region
than any other region. (Hill, et al., 2012).
The authors (Hill et al., 2012) suggested that one reason for this may be that key opinion
leaders in the region argued for the inclusion of misoprostol because, unlike oxytocin, it does not
require refrigeration. In their view, the lack of cold storage in the region may have convinced
medicines selection committees to add misoprostol. On the other hand, Magnesium sulfate
injection for treatment of severe pre-eclampsia and eclampsia was on 50% (45/89) of the lists
although they were not included consistently in national documents. Cefixime, for treatment of
uncomplicated anogenital gonococcal infection in woman was on 26% (23/89) of lists.
Tran and Bero (2015) also observed that Oxytocin was included in the essential medicine
lists (EML) of all seven countries they assessed. However, In Mongolia and the Solomon
Islands, ergometrine was not listed on the national EMLs. It was however, licensed for use in
three countries (Nepal, DPRK, the Philippines). Ergometrine and Syntometrine were
recommended as first–line drugs for PPH in Vanuatu and on the Solomon Islands, respectively.
MgSO4 injection - recommended for the prevention and treatment of eclampsia in women with
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severe pre-eclampsia was also included as an essential medicine in the national EMLs of all
seven countries.
Availability of Guidelines and Indications for Use: Tran and Bero (2015) found that
Indications for use of Oxytocin were included in the EMLs of six countries, with the exception
of the Philippines. A functional drug registration system in compliance with WHO–Good
Manufacturing Practices guideline existed in all countries except the Solomon Islands. Data for
oxytocin licensing status was not consistently reported across all seven countries. However, none
of the oxytocin formulations were licensed in Laos. Standard treatment guidelines recommended
oxytocin as a first line medicine for prevention of treatment of PPH in Laos, DPRK, and the
Philippines. In contrast, Vanuatu and the Solomon Islands recommended ergometrine or
syntometrine (combination of oxytocin and ergometrine) as a first - line drug treatment, which
was not consistent with WHO evidence–based recommendations.
Indications for use of MgSO4 injection - recommended for the prevention and treatment
of eclampsia in women with severe pre-eclampsia were clearly provided with the exception of
the Philippines. In Laos, the recommended formulation (50% solution) was not found to be
licensed or available; 20% and 15% formulations were observed in facilities. DPRK was the only
country which reported translating and utilizing treatment guidelines for pre–eclampsia and
eclampsia in partnership with WHO, UNFPA, and other national professional associations.
Furthermore, across all seven countries assessed in Tran and Bero’s (2015) study,
standard treatment guidelines were inconsistent, out–of–date, and not widely disseminated. In
Vanuatu and on the Solomon Islands, Standard treatment guidelines for prevention and treatment
of PPH and the use of ergometrine were unavailable or not updated according to the most current
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WHO clinical guidelines. These countries recommended ergometrine or syntometrine
(combination of oxytocin and ergometrine) as a first - line drug treatment, which was not
consistent with WHO evidence–based recommendations.
In contrast, Laos, DPRK, and the Philippines recommended oxytocin as a first line
medicine for prevention of treatment of PPH in line with WHO recommendation, the Standard
treatment guidelines. But overall, the use of Egometrine as second-line treatment for prevention
and treatment of PPH when oxytocin is unavailable or when bleeding does not respond to
oxytocin was limited by its side effects and contraindication in patients who have high blood
pressure.
Availability and Demand: Regarding availability of the three essential maternal health
medicines, Tran and Bero (2015) found that availability of the three medicines varied by country
and medicine. Oxytocin for example had high availability in six out of seven countries studied
compared to ergometrine. The two exceptions were the Philippines and the Solomon Islands,
where ergometrine was available in a higher percentage of facilities than oxytocin. In the same
study, four countries had MgSO4 available in less than 60% of their facilities, with only 18% of
health facilities carrying MgSO4 in Laos. According to them, calcium gluconate, a required
antidote for MgSO 4 toxicity, was not consistently available when MgSO4 was present.
Similarly, Smit et al (2014) found that the vast majority of countries (34 of 37, or 92%)
also reported regular availability of oxytocin in the national medical store or warehouse.
Oxytocin and magnesium sulfate were also reported to be regularly available (available ‘more
than half the time’’) in facilities in 89% and 76% of countries, respectively. However, only 27%
of countries studied, however, noted regular availability of misoprostol in health facilities (smith
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et al., 2014). The 4 countries that reported that oxytocin was not regularly available were
Bangladesh, Liberia, South Sudan. Smit et al (2014) also noted that evidence collected from
maternity units of hospitals with more than 1000 deliveries in Mexico and Thailand shows that
MgSO4 is underutilized in women with eclampsia.
Hill, et al., (2012). Found that demand for MgSO4 at the health center level was
apparently low, it was not clear however, if the problem of availability was due to lack of
demand leading to a lack of supply or vice versa (Ridge, Bero, & Hill, 2010). Where there was
demand by obstetricians, magnesium sulfate injection was being procured from the private sector
by the hospital pharmacy despite not being registered and licensed for use for the treatment of
severe pre-eclampsia and eclampsia by the national Medicines Regulatory Authority. However,
as this assessment did not include an audit of clinical data it is not clear if this was because there
were in fact few cases or that cases were being misdiagnosed (Ridge, Bero, & Hill, 2010). Cases
of pre-eclampsia were infrequent at small hospitals.
Affordability of maternal health medicines: In terms of affordability, these medicines appear
to be mostly provided for free. In Smith et al., (2014) study, about 70% of the countries (26 of
37) reported that oxytocin was provided for free to clients at public health facilities. In 9
countries, however, respondents reported that clients sometimes had to pay for oxytocin, even
though national policy indicates that it should be provided at no cost. A substantial number of
countries (25 of 37), however, also included diazepam for the same indication. Of the 20 SDGs
reviewed, 6 showed incomplete or inaccurate instructions for the use of magnesium in severe
PE/E, compared with the WHO standard protocol for use of the drugs.
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Accessibility of maternal health medicines: Only 51% of women in low-income countries
benefit from skilled care during childbirth (WHO, 2015). Most countries (31 of 37, or 84%)
reported that midwives/skilled birth attendants (SBAs) were authorized to perform AMTSL,
including administration of oxytocin. Fewer (29 of 37, or 78%) reported that midwives/SBAs
were authorized to diagnose severe PE/E and to administer magnesium sulfate to treat the
condition. Fewer still (26 of 37, or 70%) reported that midwives/SBAs were authorized to
perform manual removal of the placenta. Also, sixteen of 37 countries (43%) reported that they
were piloting or had piloted misoprostol for prevention of PPH at home birth; only 5 of 37,
however, reported efforts to take this program to national scale. In follow-up qualitative
responses, 7 countries reported that their governments do not support misoprostol for use at
home births.

Operational Definition of Terms
Antenatal care: Represents the care given to pregnant women before birth by skilled
health personnel that includes health promotion, screening of risk factors, and treatment of
diseases and pregnancy-related complications (WHO, 2000).
Health System: consists of all organizations, people and actions whose primary interest is
to promote, restore or maintain health (Zaidi, et al., 2013).
Health system factors: The features that characterize a health system in accordance with
the WHO six building blocks framework. These include leadership and governance, human
resources, supplies, financing, health information, and service organization (Muldoon et al.,
2011).
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Essential Medicines: Medicines that respond to the priority health needs of a specific
population (WHO, 2007).
Essential maternal health medicines: Medicines needed to prevent and treat pregnancy
and childbirth related complication (WHO, 2007). In this study, these medicines will include
oxytocin, MgSO4, and Misprostol.
Access: Availability at all times, adequate amounts, appropriate dosage forms, cost
effective, proven efficacy, quality & safety (WHO, 2014). In this study, it refers to availability at
all times, affordability and accessibility.
Availability of medicines: presence of oxytocin, MgSO4, and Misoprostol in health
facilities and central medical stores; and the frequency of oxytocin and MgSO4 stock outs in
health facilities and central medical stores.
Accessibility of Medicines: Misoprostol is piloted for home births, misoprostol is scaled
up for home births, and number of ANC visits.
Affordability of Medicines: Medicines are freely available to women in the health facility
and at home births.
Assumptions
Assumption 1
The data on access to medicines as well as health systems components may be under-or
overestimations of the current situation and may introduce bias in the weighted results. The last
survey took place about 2012. Since then, the multiple countries in the survey has experienced
repeated political and economic instability. The current statistics are based on MCHIP and WHO
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projections and may be far from reality. Using these estimates could result in under- or
overestimated results.
Assumption 2
Countries studied were representative of the other countries in the region. The process of
purposive sampling helped in selecting an unbiased sample of countries with maternal health
programs.
Assumption 3
I assumed that the data were complete and accurate and that the study participants’
answers were unbiased. Thus, I assumed that the data quality assurance and verification
measures were effective in minimizing the risk of inaccurate information recording, in particular,
duplication, wrong coding, and missing data. Additionally, I assumed that the study participants
were truthful in their answers and did not provide socially desirable responses.

Scope and Delimitations
This study assessed the relationship between one dependent variable (access to essential
maternal health medicines) and six independent variables (health system characteristics). In line
with Ishikawa diagram – a complex adaptive system model, the study will examine a subset of
determinants that could be related to access to maternal health medicines. For this reason, the
selection of the independent variables prioritizes health system characteristics.
The choice of the cross-sectional design meant that the analysis aimed to establish the
associations, not the cause-and-effect relationships or the reasons for these associations. This
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study was limited to establishing the relationships between the health system characteristics and
women’s access to essential maternal health medicines.
For this project, study participants are represented by country programs for the
prevention and management of postpartum hemorrhage and pre-eclampsia/eclampsia. The
geographical areas of focus included countries in Africa, Asia, and Latin America, focusing on
those USAID priority countries that face the highest burden of maternal morbidity. The results of
this study are generalizable to the women needing access to essential maternal health medicines
in the study areas.
Limitations
The study used a cross-sectional survey design that did not allow for manipulation of the
independent variables or establishing the temporal sequence of events. For that reason, this study
design could not establish a cause-and-effect relationship. In addition, the lack of manipulation
may have weakened the study’s internal validity.
Although the selection of study participants with ongoing national programs for
prevention of PE/E was intended to minimize recall bias, there may have remained a likelihood
of recall bias because study participants had to pull data from already existing sources.
Furthermore, the use of secondary data may result in missing other important variables
for the analysis. The analysis will depend on the data collected through the MCHIP 2012 global
survey and the WHO Pharmaceutical sector country surveys. Therefore, this study did not
identify all possible factors associated with access to maternal health medicines; variables not
collected through the MCHIP surveys and WHO Pharmaceutical sector country surveys will not
be analyzed.
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Summary, Significance, and Conclusions
Although reduced in recent years, maternal deaths due to Preeclampsia, Eclampsia, and
PPH remains high. These pregnancy-related complications and resulting maternal deaths are not
distributed evenly across the globe, but disproportionately affect women living in resources poor
settings. To reduce the incidence of these deaths, WHO recommends that oxytocin is provided as
a first-line PPH preventive intervention for facility-based deliveries and Misoprostol as an
alternative for oxytocin – which can also be used for home deliveries. MgSO4 is to be used for
treatment of PE/E.
Global and national organizations alike have implemented interventions to promote
access to these essential maternal health medicines but gaps remain. Poor and vulnerable women
still lack sufficient access to these medicines – as illustrated by current high maternal mortality
ratios in these regions. There is evidence showing that the vertical approaches that characterize
these efforts are not as effective as horizontal approaches that consider holistically, the dynamic
interaction between components of the health system and access to medicine. According to the
literature, the role of medicines is often narrowed down to a single isolated health system input
instead of an integral part of a functioning health system that affects and is affected by other
components. In this regard, the literature shows that in other to improve access to essential
maternal health medicines, it is critical to understand and incorporate the full spectrum of the
health system in research and practice regarding access to maternal health medicines (Paina and
Peters, 2011; Bigdeli et al., 2013; p.2; (Adam, Ahmad, Bigdeli, Ghaffar, & Røttingen, 2011).
These recommendations - though recently recognized - appear to be characterized by
debates regarding 1) how access to medicines should be defined, 2) which health system input
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affect access to medicines, and 3) how each health system input interact with each other and with
the desired outcome – access to and use of medicine.
In the early days, access was defined mostly from a supply side perspective. People were
thought to have access to health services if facilities that provided the services were present. But
subsequent studies started to demonstrate that this approach was less than comprehensive
because the potential to utilize a service should be perceived as different from actually utilizing a
service. Hence access should be defined and measured by actual utilization of service. Other
studies further suggested that this definition should go beyond utilization to include the extent to
which clients are able to continue utilizing services if needed.
While these dimensions of access may be applied to measuring access to pharmaceutical
products like essential maternal health medicines, researchers suggest that they present with
limitations if applied on their own. For example, defining and measuring access to
pharmaceuticals through the lens of service utilization would not be sufficiently objective since it
fails to account for the characteristics of the product delivered through a given service. It also
leaves out the role of some pertinent demand and supply related factors that are typical to
pharmaceutical products and are important aspects of a functioning health system.
As a result, a unique dimension was added by other researchers. In their view, access
should be defined by the degree of interaction between supply (the health system) and demand
(individual and household) related factors. In the last two decades, interest on this interaction
seems to have increased.
Multiple frameworks have evolved. Most emphasize the 4As proposed by earlier
researchers (Availability, Affordability, acceptability, Accessibility) but present more broadly,
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dimensions that represent access constraints beyond the health sector. Dimensions recommended
include factors related to the availability, affordability, and acceptability of products, health
service outcomes, equity of access, and equality of expenditure. Examples of factors in these
regard include time and monetary cost of seeking care (Le & 1982; Mooney,1983), household
income, service quality, personal inconvenience, cost and information.
Other dimensions include those related to governance and policies internal and external
to the health sector of a country. They include factors like public accountability and
transparency, bureaucracy in governance and dynamics of trade and economic goals for
pharmaceutical markets. International level influence like donor priority/agenda are also
highlighted as key determinants of access to medicines.
However, studies on the relationship between these factors and access to maternal health
medicines appear limited – both in number and scope (Bigdeli et al., 2012). They tend to focus
on examining the relationship between single or a few select combination of health system
factors on access to medicines, comparatively across countries – (on one occasion (Smith, 2011;
Trans and Bero, 2015; Bigdeli et al., 2015). While some use implementation research methods –
i.e. looking at how the quality of implementation program affect access - most were mixed
methods studies that included structured interviews, observations, and periodic audits. In terms
of analytical framework, some studies use the WHO health system framework, while the fish
bone Ishikawa diagram appear more popular with studies on access to essential maternal health
medicines. Common health system dimensions studied include governance and leadership, health
service delivery, pharmaceutical supply systems, financing, and human resources for health.
Common Access indicators include availability affordability, acceptability and rational use.

54
In terms of predictors of access, the most obvious themes observed in the literature
included governance, pharmaceutical supply system and quality of products and services –
although the impact of quality on access seem mixed –since quality is cross-cutting and touches
on several core levels of a health system. Common governance indicators observed include –
presence on essential medicines list, availability of necessary regulation, and national corruption
index. Pharmaceutical supply system indicators appear to be procurement and logistics related.
Examples of quality indicators that facilitate access include perception of clients, availability of
services, efficiency of service delivery infrastructures, access to antenatal care services.
However, in one study, physician density - though used as measure of quality - was not
significantly associated with access.
According to the literature, most countries studied seem to have medicines on EML, but
global variations exist. Overall Oxytocin was more prevalent on lists compared to Misoprostol.
However, misoprostol was more likely listed on WPRO region than any other region. Inadequate
provision for preservation was cited as a reason for this – since oxytocin require refrigeration but
misoprostol does not. Availability of Standard Treatment Guideline seem inconsistent across
countries. There seemed to be more demand for Oxytocin than for MGSO4. However, where
there was demand for MGSO4, it was procured from private sector – even in countries where it
is not being licensed for use for treatment. Availability of medicines in health facilities and
central stores seems to vary by country and medicine. All three medicines seem affordable in
most settings – as most are provided for free. Although in a few countries, women are made to
purchase them, even when a national policy say it should be free. Accessibility is largely
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impaired by poor access to skilled care, plus in most countries, midwives are not authorized to
diagnose PE/E and administer MGSO4.
In conclusion, several factors are said to predict access to medicines more broadly. But,
little is known about the relative impact of these dimensions on access to essential maternal
health medicines. In order to best understand how innovations and interventions will affect
access to essential maternal health medicines, the open and dynamic relationships that exist in a
health system should be analyzed more so across geographies. Predicting patterns of emergent
behavior from various sources will serve to enhance understanding and to better plan and
evaluate interventions that can lead to improved access to medicines and in turn better health
outcomes for women (de Savigny & Adam, 2009; Anderson and McDaniel, 2000; Plsek, &
Wilson, 2001).
In this quantitative cross-sectional survey, I used the Ishikawa model as theoretical
framework to examine the relationship between health system factors and women’s access to
essential maternal health medicine in Low and Middle-income Countries (LMIC). The Ishikawa
diagram was suitable for this cross-sectional analysis since it allowed for accounting for various
factors that potentially predict access at various levels, and has been previously applied to similar
studies.
The evidence from this study could guide health policy makers and program managers in
their efforts to build a health system that is responsive to the needs of rural women and children
to save lives among vulnerable populations. Because of resource and data constraints, this study
did not compare the relative impact of all factors predicting access to essential maternal health
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medicines in all geographies. So analysis was limited to a few select health system indicators in
some low and middle-income countries.

57
Section 2: Research Design and Data Collection

Introduction
This chapter describes the proposed research design and rationale, including the study
variables, the design’s connection to the research questions, and constraints related to the chosen
design. It includes the methodology—in particular, the study population, sampling technique,
procedures, measurement instruments, and data analysis plan. It also highlights the threats to
internal, external, construct, and statistical conclusion validity, and describes the ethical
procedures that will be followed, including Institutional Review Board (IRB) approvals, and
ethical concerns related to data collection and confidentiality.

Research Design and Rationale
This study was a quantitative cross-sectional survey using secondary data to determine
the relationship between health system characteristics and access to three essential maternal
health medicines. Cross-sectional surveys are commonly used research design in social sciences
(Frankfort-Nachmias & Nachmias, 2008). The cross-sectional survey design used had some
advantages and limitations. Some limitations include that it did not allow me to manipulate the
independent variables or sequence the occurrence of events. For that reason, causal inferences
and before-and-after comparisons was not possible (Frankfort-Nachmias & Nachmias, 2008).
Further, it may have introduced recall bias since primary data was collected from information
collected in the past (Rossetti, 2015).
Despite these limitations, the cross-sectional survey design was most appropriate for this
non-experimental analysis. It gave a snapshot of the situation in the study location and allowed
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for comparison between different or similar geographies at a point in time. This design also
allowed for ease of administration of data collection materials telephone interviews, online
platforms, mobile devices, mail, email, or computer kiosks. It also allowed for collection of large
amounts of data to increase statistical power and allow more sophisticated analysis. It was cost
effective when compared with experimental and cohort studies (Rossetti, 2015). As such, the use
of secondary data for analysis in this study saved cost and time, and enhanced the privacy of
study participants (Frankfort-, Nachmias & Nachmias, 2008).
Study Variables
The study aimed to investigate the nature of association between health system
characteristics (the independent variables) and access to three essential maternal health
medicines – the dependent or outcome variable. Frankfort-Nachmias and Nachmias (2008)
defined dependent variables as those for which researchers work to explain change, and
independent variables as those that explicate change in the dependent variables.
The independent variables were health-system characteristics that may influence
women’s access and use of these medicines. In this regard, five health system levels or domains
was assessed: government and regulatory, pharmaceutical supply system, health facility, health
financing, and health professional (health services). For each domain, two to three health system
variables that best represent a domain were analyzed (table 3.1). The outcome variable for this
study was ‘access’, defined as the availability, affordability and accessibility three essential
maternal health medicines combined (Oxytocin, Egometrin and Magnesium Sulfate).
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Table 3
Health System Determinants of Access to Maternal Health Medicines
Variable/Domain

Questionnaire Item

Governance/Regulation

1.Medicines approved at national level
2. Availability of Standard Treatment
Guidelines
3. Policy provision for AMTSL
4.Good Governance
Pharmaceutical Supply
5.Procurement/ Logistics
Health Facility
6. Adequate Equipment’s and Supplies
7. Education/Trainings
Service Delivery
8. Adequate human resources
9. Midwife/skilled birth attendants scope of
practice
Health Financing
10.National Health spending
Note. These are the 5 health system characteristics identified as independent variables for the
purpose of this study
Research Design Connection to the Questions and Scientific Knowledge
This study investigated the relative effect of selected health system factors on access to
three live-saving maternal health medicines (Oxytocin, Misoprostol and Magnesium Sulfate).
Past research has examined similar questions through mixed-method studies without
manipulation and secondary data analysis of cross-sectional surveys. In that regard, the crosssectional survey design used in this study has remained a popular research design in studies of
the determinants of access to medicines and health systems (Ridge et al., 2010; Bigdeli, Zafar,
Assad, & Ghaffar, 2013; Muldoon et al (2011; Denton, et al.,1990; and Akin, et al., 1990)
A cross-sectional household survey was considered more relevant for this study because
of the paucity of data on access to live saving maternal health medicines. This study was
implemented as a secondary analysis of data from quantitative cross-sectional facility and
household surveys conducted independently by the World Health Organization (WHO) and the
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United States Agency for international development (USAID) Maternal and Child Health
Integrated Program (MCHIP).
As Frankfort-Nachmias and Nachmias (2008) observed, a secondary data analysis is less
expensive than studies requiring primary data collection. In advancing knowledge, this study will
be an initial step in establishing the relative effects of health system characteristics and access to
essential maternal health medicines. It will lay the ground for further studies.
Methodology
Target Population
The USAID MCHIP survey included countries from Africa, Asia and Latin America focusing on those USAID priority countries that face the highest burden of maternal morbidity.
The WHO survey proposed for this study – the WHO pharmaceutical sector country survey was
a comprehensive assessment of the pharmaceutical sector in countries in the same region.
Settings
The WHO pharmaceutical sector survey was implemented in nearly all WHO countries.
In 2010, the country profiles project was piloted in 13 countries during 2011, the World Health
Organization had supported all WHO Member States to collect similar pharmaceutical country
data. It is a comprehensive assessment of the pharmaceutical sector aimed to measure key
aspects of the pharmaceutical sector and systematically monitor the progress of efforts to
improve access to essential medicines.
The USAID MCHIP survey assessed 37 national programs for the prevention and
management of PPH and PE/E. The survey has been implemented twice (2011 and 2012). It
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captured a cross-section of countries that are either priority countries within USAID’s global
health strategy, or engaged in relevant maternal mortality reduction efforts.
Sampling and Sampling Procedures
A sample is a subset of sampling units that has the attributes of the target population. It
has to be representative to allow generalization of the findings to the entire population
(Frankfort-Nachmias & Nachmias, 2008). In this study, the sampling unit was a country that
implemented a national program for the prevention and management of PPH and PE/E, and
participated in USAID MCHIP survey.
There are two main sampling designs: probability sampling and nonprobability sampling.
This study will use the purposive non-probability sampling to base on set criteria (FrankfortNachmias & Nachmias, 2008). The inclusion criteria were countries with a national program for
the prevention and management of PPH and PE/E who participated in the USAID MCHIP
survey. The exclusion criteria included countries that did not participated in the USAID MCHIP
survey.

Procedures for Archival Data
Main Study Data Collection
MCHIP Survey: Data collection was coordinated by the MCHIP maternal health team in
Washington, D.C., during the months of January, February and March 2012. Contact information
was compiled for an identified focal person in each of the 43 countries initially targeted by the
survey. The contact list from 2011 was used and the individual’s continuing engagement with
national activities was confirmed. Additional sources were contacted in an effort to ensure that
there was an appropriate coordinator for the data-gathering activities in each country.
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The coordinator for each country was sent an e-mail with anticipated dates and activities
six weeks in advance of receiving the survey. He or she was instructed to contact national
counterparts in the government as well as leading implementing partners. The country
coordinator was given a timeline of pending requests and asked to arrange meetings with
national consultative groups to ensure a national participatory process for the completion of the
survey instruments. In most cases this was possible. Key stakeholders from government,
ministries, MCHIP programs, other USAID bilateral programs, UN partners and other
implementing agencies met to collect data and respond to the 46-item questionnaire and the
scale-up map. In most cases, these consultative groups found it necessary to meet twice to ensure
accuracy and completeness of responses.
The questionnaire and scale-up maps were revised from the 2011 versions, based on
responses, questions and feedback from the 2011 survey administration. Surveys were sent out
via e-mail in English French and Spanish, and countries received copies of their 2011 surveys,
which served as a starting point. Stakeholders met in-country to collect data and respond to the
survey, and contacted the MCHIP maternal health team with questions. Responses were shared
via e-mail in English, French and Spanish. Professional translators translated French and Spanish
survey responses into English.
WHO pharmaceutical sector country survey: Data collection in all 193 member states
was conducted using a user-friendly electronic questionnaire that included comprehensive
instruction manual and glossary. Countries were requested to enter the results from previous
surveys and to provide centrally available information compiled data comes from international
sources (e.g. the World Health Statistics), surveys conducted in the previous years and country
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level information collected in 2011.
Access to the dataset and permissions: Data set for both surveys are publicly available
and can be found on the website of both organizations. An email will be sent to contact persons
in both organizations to clarify any limitations to the use of data by the public for secondary
analysis. Where relevant a data use agreement will be provided to clarify the details of the data
elements needed, the responsibilities of the data provider and beneficiaries, and the boundaries of
the data use.
Instrumentation and operationalization of constructs: The main source of information
for this study will be the limited dataset provided by the WHO pharmaceutical sector country
profile, and USAID MCHIP survey data - which contains the identified information. It includes
relevant sociodemographic characteristics, health-system characteristics and access indicators for
each country. Information on the health system characteristics encompassed indicators in five
domains – government/regulator, pharmaceutical supply, health facility, health service delivery,
and information systems – as shown in table 3.1.
The 46-item questionnaire included six core components: policy, training, drug
distribution and logistics, national reporting of key maternal health indicators, programming, and
challenges to and opportunities for scale-up.
Operationalization of Variable
Independent Variables
Independent variables for the study included: Medicines Approved at National Level,
Accessibility of Standard Treatment Guidelines, Policy Provision for Active management of
third stage of labor (AMTSL), Good Governance, Procurement and Logistics, Equipment’s and

64
Supplies, Education/Training, Human Resources, Midwife/Skilled Birth Attendant Scope of
practice, Health Spending, National Reporting on Selected Maternal Health Indicators. The
USAID MCHIP survey instrument suggest that data was collected on these variables as outlined
in Appendix 1:
Dependent Variable
The dependent variables included the availability, and accessibility of the three medicines
in focus for this study. The USAID MCHIP survey gathered data on these variables as follows:
Availability of medicines: The dataset included information on the availability of
oxytocin, MgSO4, and Misoprostol in health facilities and central medical stores; and the
frequency of oxytocin and MgSO4 stock outs in health facilities and central medical stores.
Accessibility of Medicines: the dataset included information about home birth and ANC
attendance. Specifically, data was collected on whether misoprostol is piloted for home births,
misoprostol is scaled up for home births, and number of ANC visits.
Affordability of Medicines: The dataset included information on whether these
medicines are freely available to women or not.
Data Analysis Plan
Statistical Software.
IBM SPSS Statistics 21 software was used to analyze data collected. The software was
used to run both the descriptive and inferential analyses.
Data Cleaning and Screening Procedures.
Dataset contained about 41 variables needed for this analysis. As a first step, data was
coded and inputted into SPSS. As next step, I produced frequency tables by variable to assess for
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irregular entries. This step help me to check for coding errors, missing data, and outliers.
Variables that have either outliers or more than 5% missing data were identified and excluded.
Research Questions and Hypotheses
The Study had five research questions:
Research Question One
1. Is there a significant association between governance and access to essential maternal
health medicines in low and middle-income countries?
Ho1: there is no significant association between governance and access to essential
maternal health medicines in low and middle-income countries?
Ha1: there is a significant association between the governance and access to essential
maternal health medicines in low and middle-income countries?
Research Question Two
2. Is there a significant association between pharmaceutical supply and access to essential
maternal health medicines in low and middle-income countries?
Ho2: there is no significant association between pharmaceutical supply and access to
essential maternal health medicines in low and middle-income countries?
Ha2: there is a significant association between pharmaceutical supply and access to
essential maternal health medicines in low and middle-income countries?
Research Question Three
3. Is there a significant association between the quality of health facility and access to
essential maternal health medicines in low and middle-income countries?
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Ho3: there is no significant association between the quality of health facility and access
to essential maternal health medicines in low and middle-income countries?
Ha3: there is a significant association between the quality of health facility and access to
essential maternal health medicines in low and middle-income countries?
Research Question Four
4. Is there a significant association between quality of service delivery and access to
essential maternal health medicines in low and middle-income countries?
Ho4: there is no significant association between quality of service delivery and access to
essential maternal health medicines in low and middle-income countries?
Ha4: there is a significant association between quality of service delivery and access to
essential maternal health medicines in low and middle-income countries?
Research Question Five
5. Is there a significant relationship between health financing and access to essential
maternal health medicines in low and middle-income countries?
Ho5: there is no significant association between health financing and access to essential
maternal health medicines in low and middle-income countries?
Ha5: there is a significant association between health financing and access to essential
maternal health medicines in low and middle-income countries?
Statistical Analysis.
Data Weighting.
The primary study selected a disproportional sample of 37 countries from Asia, Africa
and Middle East regardless of continent. Therefore, the preparation for data analysis will include
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the data weighting to account for population size (no of countries) differentials between the
continents.
Testing for Multicollinearity.
Before running the full analysis, I tested for multicollinearity to ascertain the
independence of independent variables from each other. Forthofer, Lee, and Hernandez (2007)
defined multicollinearity as a significant correlation between independent variables that can
negatively affect the regression estimates by inflating the variance and standard errors.
Multicollinearity occurs when an independent variable is a duplicate of another variable or is a
redundant variable that measures the same thing. The analysis included a pairwise correlation
analysis that correlated independent variables with each other in a bivariate correlation matrix.
Any bivariate correlation equal or above .80 was considered an indication of a potential
collinearity between two variables (Field, 2013).
I also calculated the tolerance and variance inflation factor (VIF). Field (2013) defined
Tolerance as the proportion of variance in the independent variable not attributable to the other
independent variable: 1-R 2. The higher the tolerance, the lower the risk of multicollinearity. A
tolerance of .10 or less is considered problematic. Likewise, the VIF reflects an inflation of the
standard error due to multicollinearity: 1/ (1-R2). A VIF of 10 or more is considered problematic
(Field, 2013; Forthofer et al., 2007).
Checking for Outliers.
I checked for the presence of outliers on originally numerical variables. Field (2013)
defined outliers as values that are either extremely high or extremely low in the data (Field,
2013). They have the potential to skew the data in one direction or the other and bias the
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statistics. I will use the descriptive analysis function of SPSS to compare the mean and trimmed
mean – mean without the 5% lowest and highest values – to see if there is a considerable
difference. Besides, Z scores were created to identify outliers as all values with Z scores above
3.29. Furthermore, a graphic presentation using histograms and boxplots was used to spot the
outliers.
Descriptive Analysis.
The first step was to compute a total score for all items representing each variable (in
table 3.1) and set cut-off score for variable categories. Then convert each variable into
dichotomous variable (e.g. Highly available, Poorly available; highly accessible, poorly
accessibility; highly affordable, poorly affordable).
The second step of the descriptive analysis included a chi-square test to analyze the
proportion of countries by variable category and estimate the standard deviations. The
comparison also focused on comparing each variable category with sociodemographic
characteristics, and each independent variable. A p-value < .05 was considered statistically
significant. The variables achieving a p-value < .05 indicated the characteristics of difference
between the two groups of countries. These two analyses will help to identify the independent
variable categories with high access.
Inferential Analysis.
For the inferential analysis, applied the logistic regression in two steps to assess the
association between health system variables and access to focus medicines.
First step or Model 1. included a bivariate analysis of the crude association between
each of the 6 dimensions and 16 health system variables (table 3.1) and two control variables
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(sociodemographic variables.) and high access to medicines (dependent variable). The results
was presented as crude OR, 95% CI, and p-value.
Second step or Model 2. included a multivariate analysis of the adjusted association
between health system variables with p< .05 identified during the bivariate analysis and high
access to medicines (dependent variable). A hierarchical order of factors to be included in the
first iteration was the variables of governance/regulation. The second iteration included the
variables of health facility. The third iteration included variables of health service delivery. The
forth iteration included variables of pharmaceutical supply. The fifth iteration included variables
of data collection/information systems; and The sixth iteration included variables of health
financing. The multivariate adjusted logistic regression analysis was controlled for confounders
that have a p< .05 in the bivariate analysis of their association with high access to medicines. The
results are represented as the Adjusted OR, 95% CI, and p-value.

Threats to Validity
External Validity: There is a threat to external validity when the findings are
erroneously generalized to individuals who do not have the study participants’ characteristics,
places that do not have the study setting characteristics, and different past or future situations
(Creswell, 2013). The primary study minimized the threats to external validity by ensuring data
was collected and confirmed with relevant stakeholders within each country. This helped to
ensure the representativeness of the study participants to the target population. Besides, this
study will restrict the generalization of its findings and claims to similar population groups and
settings to enhance its external validity (Creswell, 2013).
Internal validity: Creswell (2013) observed that threats to internal validity include the
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procedures, treatments, and participants’ characteristics that may restrict the researcher’s ability
to draw meaningful conclusions. In this study, the threats to internal validity were limited
because of the use of secondary data. Besides, the random selection of participants in the primary
study minimized the selection bias. Furthermore, the cross-sectional survey design with no
experiment did not allow for the effect of history, maturation, regression, mortality, diffusion of
treatment, testing, instrumentation, and selection-maturation interaction.
Construct validity: Creswell (2013) reported that threats to construct validity occur
when variable definitions and measures are inadequate. This study maintained the same
definitions and measures of variables used in previous studies of ANC utilization and
compliance (Joshi et al., 2014; Mugo et al., 2015; Trinh et al., 2007; Tsegay et al., 2013).
Statistical conclusion validity: The threat to statistical conclusion validity occur when
the study findings are not accurate because of insufficient statistical power or the violation of key
assumptions (Creswell, 2013). In this study, I used a sufficient sample of all 37 resource poor
countries with a maternal health program that participated in the MCIP survey so that they
achieve a computed power of .80 or more on all independent variables.
Besides, I ensured that the study met the assumptions required for a logistic regression
analysis. First, the dependent variable – Access to medicines – was transformed into a
dichotomous variable with two categories: High access and poor access based on z-scores
computed for all measures in each variable category. Second, I assigned the code 1 to the
category of ‘high access’ as the desired outcome. Third, only the variables with p< .05 on
bivariate analysis were included in multivariate analysis through a hierarchical stepwise method.
Fourth, I tested for multicollinearity to ensure the independent variables are independent of each
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other. Fifth, I assessed for outliers and missing data and use multiple imputations to replace the
missing data. Last, the study included an adequate sample size and the minimum number of
cases per variable category was 18.
Ethical Procedures
To ensure the protection of the study participants’ rights, I have taken the web-based
ethics training of the National Institutes of Health (NIH) Office of Extramural Research. The
course intended to raise the awareness of researchers working with human subjects regarding
their obligations towards the rights and welfare of human subjects in the conduct of research.
The NIH certificate of completion is in Appendix B.
Protection of Participants’ Rights
This study used secondary data that have the advantage of enhancing the participants’
privacy as I did not interact directly with the study participants. In addition, the limited dataset
did not include personal identifiers to prevent linking the data to the study participants.
Furthermore, the Walden University IRB approved this study to ensure that it fully meets the
required ethical standards.
Data Protection
The limited dataset was stored on a password-protected computer with a backup on a
password-protected hard drive. I will keep the data for 5 years after the end of the study and
destroy it using appropriate. The results of this study were aggregated to protect the privacy of
the study participants. I disseminated the results to WHO, USAID MCHIP, in national and
international conferences, and through peer-reviewed journals.
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Summary
This study was a quantitative cross-sectional survey using secondary data collected by the
WHO pharmaceutical country survey and USAID MCHIP survey. Walden University IRB
approved the study after verifying that it met the required ethical standards.
The sample included 37 countries that participated in the USAID 2012 MCHIP survey
The dependent variable access to essential maternal health medicines defined by availability,
affordability and accessibility of essential maternal health medicines.
The independent variables included measures such as if medicines are approved at
National Level, Accessibility of Standard Treatment Guidelines, Policy Provision for Active
management of third stage of labor (AMTSL), Good Governance, Procurement and Logistics,
Equipment’s and Supplies, Education/Training, Human Resources, Midwife/Skilled Birth
Attendant Scope of practice, Health Spending, National Reporting on Selected Maternal Health
Indicators. Data was analyzed using the IBM SPSS Statistical software version 21. It included a
descriptive analysis of each country’s characteristics as well as bivariate and multivariate logistic
regressions of the health system characteristics that best predict access to essential maternal
health medicines. Chapter 4 that follows will describes the secondary data analysis and presents
its results.
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Section 3: Results
Introduction
The purpose of this quantitative cross-sectional survey using secondary data analysis was
to investigate the association between health-system characteristics and access to maternal health
medicines. The study participants included 37 low and middle-income countries who participated
in USAID MCHIP and WHO pharmaceutical 2011/2012 survey. I used the IBM SPSS Statistics
21 software to answer the questions and test the hypotheses listed below:
Question 1: Is there a significant association between governance and access to essential
maternal health medicines in low and middle-income countries?
Ho1: there is no significant association between governance and access to essential
maternal health medicines in low and middle-income countries?
Ha1: there is a significant association between the governance and access to essential
maternal health medicines in low and middle-income countries?
Question 2: Is there a significant association between pharmaceutical supply and access
to essential maternal health medicines in low and middle-income countries?
Ho2: there is no significant association between pharmaceutical supply and access to
essential maternal health medicines in low and middle-income countries?
Ha2: there is a significant association between pharmaceutical supply and access to
essential maternal health medicines in low and middle-income countries?
Question 3: Is there a significant association between the quality of health facility and
access to essential maternal health medicines in low and middle-income countries?
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Ho3: there is no significant association between the quality of health facility and access
to essential maternal health medicines in low and middle-income countries?
Ha3: there is a significant association between the quality of health facility and access to
essential maternal health medicines in low and middle-income countries?
Question 4: Is there a significant association between quality of service delivery and
access to essential maternal health medicines in low and middle-income countries?
Ho4: there is no significant association between quality of service delivery and access to
essential maternal health medicines in low and middle-income countries?
Ha4: there is a significant association between quality of service delivery and access to
essential maternal health medicines in low and middle-income countries?
Question 5: Is there a significant relationship between health financing and access to
essential maternal health medicines in low and middle-income countries?
Ho5: there is no significant association between health financing and access to essential
maternal health medicines in low and middle-income countries?
Ha5: there is a significant association between health financing and access to essential
maternal health medicines in low and middle-income countries?

Data Collection
Data set for both surveys are publicly available and can be found on the website of
WHO and USAID MCHIP. There was no discrepancy between the plan presented in Chapter 3
and the actual data collection.
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Primary data for the MCHIP survey was coordinated by the MCHIP maternal health team
in Washington, D.C., during the months of January, February and March 2012. Contact
information was compiled for an identified focal person in each of the 43 countries initially
targeted by the survey. An identified coordinator for each country was sent an e-mail with
anticipated dates and activities six weeks in advance of receiving the survey. He or she was
instructed to contact national counterparts in the government as well as leading implementing
partners. The country coordinator was given a timeline of pending requests and asked to arrange
meetings with national consultative groups to ensure a national participatory process for the
completion of the survey instruments. In most cases this was possible. Key stakeholders from
government, ministries, MCHIP programs, other USAID bilateral programs, UN partners and
other implementing agencies met to collect data and respond to the 46-item questionnaire and the
scale-up map. In most cases, these consultative groups found it necessary to meet twice to ensure
accuracy and completeness of responses.
The WHO pharmaceutical country survey data was collected from all 193 member states
using a user-friendly electronic questionnaire that included comprehensive instruction manual
and glossary. Countries were requested to enter the results from previous surveys and to provide
centrally available information compiled data comes from international sources (e.g. the World
Health Statistics), surveys conducted in the previous years and country level information
collected in 2011.
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Inclusion and Exclusion Criteria
The original MCHIP survey dataset included records of 37 countries from Africa, Asia
and the Americas; while those of WHO country surveys included records for 193 member
countries. The records were assessed for eligibility based on the inclusion and exclusion criteria.
Countries were included if they participated in the USAIDS MCHIP survey. They were excluded
if they did not participate in the MCHIP survey.
Review of Statistical Assumptions
The study analysis included standard multiple regressions on one outcome variable
(Access to live-saving maternal health medicines) and six independent variables (Strength of
health system governance, pharmaceutical procurement and distribution, quality of health
services and facilities, health care financing, and reporting of relevant maternal health medicine
indicators). Responses to forty-four numeric and string question items that best represented these
variables were collected and grouped to form composite variables for the regression analysis. I
reviewed the key assumptions of logistic regression analysis, in particular, the magnitude of
missing data, presence of multi-collinearity and outliers, and the compliance with a minimum of
10 cases per variable category.
Outliers. Using Z-score method to identify outliers, analysis showed that data were
positively skewed in four numeric indicators (number of hospital beds per 10,000; pharmacist
per 10,000pop; and physicians per 10,000 population and Nurses and midwives per 10,000
population) with skewness ranging of 4.148, 3.154, 4.891, 2.910 respectively. To make data
normally distributed and suitable for further analysis, I applied a two-step process. Data were
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first ranked using SPSS transform function. They were then transformed and computed to form
new variables using SPSS Transform and IDF normal function.
Missing data. The first part of the missing data analysis showed that 17 of the 44
indicators for the independent and dependent variables included in the study had some missing
data. The top five indicators were: public insurance coverage for medicines on EML (43.2%),
Access to essential Medicines as part of fulfilment of the right to health (43.2%), Total health
expenditure as percent of GDP (37.8%), availability of national guidelines for good distribution
practices (37.8%), and presence of public sector procurement policies (35.1%).

Figure 2. Summary of missing data in the study database. Generated from SPSS multiple
imputation analysis of missing data patterns.
High rates of missing data can introduce bias and compromise the validity of the study
findings. Analysis of missing value patterns suggested some monolithic pattern of missing values
across some variables. Multiple imputations, one of the most recommended missing data
handling techniques, were used to replace the missing values with five imputations based on the
predictive values derived from the observed data (Sterne et al., 2009).
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Multicollinearity. Another test was a bivariate correlation analysis of the 12 independent
variables in SPSS using the Pearson correlation coefficient. The results showed no value of the
Pearson correlation coefficient equal or above .80, confirming that there was no multicollinearity
between the variables of interest. All the correlation coefficients were below .60. The second test
was the collinearity diagnostics in linear regression that examined the tolerance rate and variance
inflation factor (VIF) (Field, 2013). The results found no tolerance rate below .10 or VIF above
10. All the tolerance values were above .70 and VIF below two, indicating that there was no
multicollinearity.
Sample Size and Minimum Number of Cases in Each Variable Category.
As a rule of thumb, each category of the independent variables included in logistic
regression analysis must have a minimum of 10 cases (Vittinghoff & McCulloch, 2007). In that
regard, the total sample of 37 was large enough to achieve sufficient statistical power. Some
categories of the independent variables were combined to satisfy the rule of 10. The lowest cell
count was 27 cases. All the other categories had more than 27 cases.
Variable Categorization and Coding
The analysis included one outcome and six independent variables. Responses to fortyfour numeric and string question items that best represented these variables were collected and
combined to form composite dichotomous variables for the regression analysis.
The outcome variable, Access to Medicines had three variables (coded 1. Yes, 2. No):
availability of medicines, affordability of medicines, accessibility of medicines. Countries with
less than 50% of the combined scores were assumed to have poor access (coded: 0,) while those
with above 50% of combined score, good access (desired outcome, coded 1).
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Similar procedures were used to organize the six independent variables. Strength of
Health System Governance (coded 1 strong health system governance, 2. Weak health system
governance) comprised of three items: medicine is approved at national level, guidelines for
treatment are available, access to medicines and technologies are recognized as part of the right
to health. Health system procurement, distribution and supply variable (coded, 1. Strong, 2.
Weak) comprised of two items: medicines procurement system, medicines distribution and
supply system. Quality of health facility variable (coded 1. High quality, 2. Poor quality) had one
item: Number of hospital beds per 1000 population. Similarly, the quality of health services
variable (coded 1. High quality, 2. Poor quality) had three items (adequacy of human resources
for health, comprehensiveness or education and trainings for human resources for health,
Midwife and Birth attendants scope of practice. Health system financing (coded 1. Robust 2. Not
robust) had three items: Total health expenditure as % of GDP, Total Pharmaceutical,
expenditure as % of health expenditure, private health expenditure as % of total health
expenditure. Finally, the sixed variable – reporting of key maternal health medicines (coded 1.
Strong reporting and 2. reporting had a single item: national reporting on key maternal medicines
indicators
Descriptive Analysis
About 53% of countries enrolled in the study reported relatively good access to essential
maternal health medicines compared to 47% that reported poor access – based on three
indicators: availability, affordability, and accessibility of essential maternal health medicines.
Medicines were often (75% of the time) available in only 24% of countries, affordable in 56% of
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countries and accessible in 13.5% of countries. Oxytocin was more readily available (75% of the
time) in 44% of countries compared with MgSO4 in 37% of countries.
Regarding health systems governance, more countries (61.7%) recognize access to
medicines as a right to health in their constitution compared with those that had maternal health
medicines on their EML (52.8%) and had guidelines treatment (49.3%). However, amongst all
three indicators for strength of health system governance, availability of medicines on the EML
seemed to have a statistically significant relationship with access to medicines (p<0.001).
Countries seemed to have better medicine procurement systems than distribution systems.
More countries (62%) had strong procurement systems than they did strong distribution systems
(and 44% respectively). Independently cross-tabbed, neither of these indicators showed
statistically significant association with the outcome variable. In terms of quality of health
facilities, only 24% of countries reported relatively substantial infrastructures for health and this
indicator had a statistically significant association with access to essential maternal health
medicines (p <0.001).
Results differed slightly with indicators for quality of health services. Comparatively,
their appeared to be the most gap in midwives and birth attendants scope of practice among
countries. Nearly half (45%) of countries reported less comprehensive education and trainings
for human resources for health while a little more than half (59% and 67% respectively) reported
relatively less adequate human resources for health and narrow scope of practice for midwives
and birth attendants. Except for education and training, other indicators for quality of health
services showed statistically significant associations with the outcome variable. Few countries
(14% and 35% respectively) appeared to have robust health system financing and report key
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maternal health medicines indicators. These indicators showed statistically significant
association with access to essential maternal health medicines.

1
Table 4
Background Characteristics of the Countries
Variables

Characteristics

Health System
Governance

Medicines Approved at
National Level
Availability of Standard
Treatment guidelines
Access to Medicine
recognized as right to
Health in Constitution

Medicine
Procurement,
Distribution and
supply System

Quality of Health
facilities
Quality of Health
Services

Robustness of Health
Financing
National Reporting
of Key Maternal
Health Medicine
Indicators

Strong Medicine
Procurement System
Strong Medicine
Distribution &Supply
System
Have Substantial
Infrastructure.
Human resources for
Health have
Comprehensive
Education and Training
Human Resources for
Health are relatively
substantial
Midwives/Birth
Attendants have broad
Scope of Practice
Health and
pharmaceutical
expenditure
Strong National
Reporting of Key
Maternal Health
Medicine Indicators

All
countries
n (%)

Yes
<50%
n (%)

ChiSquare

Pvalue

36(100)

19(53) 17(47)

37(100)

18(49) 19(50) 26.260

0.000

37(100)

23(62) 14(38)

37(100)

23(62)

No
>50%
n (%)

14(38)

37(100)

16(44) 21(54)

37(100)

24(65) 13(34) 14.300

0.000

37(100)

20(54) 17(45) 5.896

0.015

37(100)

15(41) 22(59)

37(100)

12(33) 25(67) 4.434

0.035

37(100)

5(14)

0.000

37(100)

12(35) 25(65) 8.680

32(85) 38.068

0.003
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Statistical Analysis Findings by Research Questions and Hypotheses
The analysis report below includes the outcomes of bivariate and logistic regression
analyses, based on a sample of 37 resource poor countries in Africa, Asia, and America who met
the inclusion criteria. The first step was a bivariate (Chi-square) analysis of the association
between six independent variables (Health system Governance, medicine procurement,
distribution and supply, quality of health facilities, quality of health services, health financing
and data reporting for key maternal health medicines.) and Access to essential maternal health
medicines. Findings showed that all the independent variables, with the exception of quality of
health services had a statistically significant association with access to maternal health medicines
and achieved a p-value < .05. The second step included a multiple logistic regression analysis to
test which of the five independent variables that had a statistically significant association with
the outcome variable and a p-value < .05. significantly predicted access to essential maternal
health medicines. The results of the regression indicated that three predictors explained 27% of
the variance (R2 =.266, F(5,162)=13.12, p<.01). It was found that the strength of a country’s
medicine procurement, distribution, and supply system significantly predicted access to essential
maternal health medicines (β= -.41, p<.001), as did robustness or health system financing (β= .51, p<.001), and quality of health facilities (β= -.34, p<.05).

Research question 1. The first question was stated as follows: Can access to live-saving
maternal health medicines be predicted based on the strength of a country’s health system
governance?
Ho1: Access to essential maternal health medicines cannot be predicted based on the
strength of a country’s health system governance?
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Ha1: Access to essential maternal health medicines can be predicted based on the
strength of a country’s health system governance?
A chi-square test of independence was performed to examine the relation between
strength of health system governance and access to live-saving maternal health medicines. The
vast majority (71.8%) of countries enrolled in the study had weak health system governance as
compared to 28.2% with strong health system governance.
The standardized deviations to measure the magnitude of the difference between
observed and expected values on women’s access to essential maternal health medicines by the
strength of a country’s health system governance (Spiegel, Schiller, and Srinivasan, 2009)
showed that stronger health system governance had a negative deviation towards poor access to
essential maternal health medicines. The inverse direction was observed for relatively weaker
health system governance (table 6). A negative standardized deviation indicates that the observed
values are lower than expected and a positive standardized deviation that the observed values are
higher than expected. More countries (28%) with weaker health system governance had poor
access to essential maternal health medicines compared with those with strong health system
governance (11%).
Table 5
Standardized Deviations of Health System Governance by Access to Maternal Health Medicines

Health
Systems
Governance

Strong
Weak

Access to Maternal Health Medicines
Good
Poor
+1.6
-3.3
-1.0
+2.1
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The bivariate analysis showed a statistically significant association between health
system governance and access to essential maternal health medicines χ(1) = 18.999, OR =
1.368, CI [ 1.239, 1.150], p = .000. This finding may suggest that women in countries with
stronger health system governance were more likely to have better access to maternal health
medicines than those in countries with weaker health system governance. However, a
multivariate analysis that followed did not retain the statistically significant association
between the strength of health system governance and access to essential maternal health
medicines (β= -.160, t = -1.351, CI [ -0.394, 0.074], p =.178). Therefore, I accept the null
hypothesis and conclude that access to essential maternal health medicines cannot be predicted
based on the strength of a country’s health system governance.
Research question 2. The second question was stated as follows: Can access to essential
maternal health medicines be predicted based on the strength of a country’s medicine
procurement, distribution, and supply system?
Ho2: Access to essential maternal health medicines cannot be predicted based on the
strength of a country’s medicine procurement, distribution, and supply system?
Ha2: Access to essential maternal health medicines can be predicted based on the
strength of a country’s medicine procurement, distribution, and supply system?
A chi-square test of independence was performed to examine the relation between
strength of Medicine procurement, distribution and supply system and access to essential
maternal health medicines. The vast majority (64.3%) of countries enrolled in the study had
weak medicine procurement, distribution and supply system compared to 35.7% with strong
medicine procurement, distribution and supply system.
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The standardized deviations to measure the magnitude of the difference between
observed and expected values on women’s access to essential maternal health medicines by the
strength of a country’s health system governance (Spiegel, Schiller, and Srinivasan, 2009)
showed that stronger medicine procurement, distribution and supply system had a negative
deviation towards poor access to essential maternal health medicines (table 6). A negative
standardized deviation indicates that the observed values are lower than expected and a positive
standardized deviation that the observed values are higher than expected.
More countries (24.8%) with weaker medicine procurement, distribution and supply had
poor access to essential maternal health medicines compared with those with strong Medicine
procurement, distribution and supply system (8.1%).
Table 6
Standardized Deviations of Medicine procurement, distribution and supply by Access to
Maternal Health Medicines

Medicine
procurement,
distribution and
supply

Strong
Weak

Access to Maternal Health Medicines
Good
Poor
+1.0
-2.1
-.8
1.6

The bivariate analysis showed a statistically significant association between medicine
procurement, distribution and supply system and access to essential maternal health medicines
χ(1) = 8.676, OR = 3.740, CI [ 1.486, 9.411], p = .003.
A multivariate analysis that followed retained the statistical significant association
between medicine procurement, distribution and supply system of a country and access to
essential maternal health medicines (β= -.411, t = - 3.641, CI [ - 0.634, -.188], p <0.001). These
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findings suggest that women in countries with stronger health medicine procurement, distribution
and supply systems were more than 3 times more likely to have better access to maternal health
medicines than those in countries with weaker medicine procurement, distribution and supply
system. Therefore, I reject the null hypothesis and conclude that access to essential maternal
health medicines can be predicted based on the strength of a country’s medicine procurement,
distribution and supply system.

Research question 3. The third question was stated as follows: Can access to essential
maternal health medicines be predicted based on the quality of health facilities in a country?
Ho3: Access to essential maternal health medicines cannot be predicted based on the
quality of health facilities in a country
Ha3: Access to essential maternal health medicines can be predicted based on the quality
of health facilities in a country.
A chi-square test of independence was performed to examine the relation between quality
of health facility and access to live-saving maternal health medicines. The vast majority (65.6%)
of countries enrolled in the study had relatively good quality health facilities compared to 34.4%
with poor quality.
The standardized deviations to measure the magnitude of the difference between
observed and expected values on women’s access to essential maternal health medicines by the
strength of a country’s health system governance (Spiegel, Schiller, and Srinivasan, 2009)
showed that countries with good quality health facilities had a negative deviation towards poor
access to essential maternal health medicines (table 6). The reverse was the case for countries
with poor quality health facilities. A negative standardized deviation indicates that the observed
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values are lower than expected and a positive standardized deviation that the observed values are
higher than expected.
More countries (33.7%) with poor quality health facilities had poor access to essential
maternal health medicines compared with those with higher quality health facilities (11.7%).

Table 7
Standardized Deviations of Quality of Health Facilities by Access to Maternal Health Medicines

Quality of
Strong
Health Facilities Weak

Access to Maternal Health Medicines
Good
Poor
+1.0
-2.0
-1.3
+2.8

The bivariate analysis showed a statistically significant association between quality of
health facilities and access to essential maternal health medicines χ (1) = 14.600, OR = 3.781, CI
[ 1.849, 7.733], p <0.001. A multivariate analysis that followed retained the statistical significant
association between the quality of health facilities in a country and access to essential maternal
health medicines (β= -.342, t = - 3.055, CI [ - 0.563, -.121], p <0.05). These findings suggest that
women in countries with higher quality health facilities were more likely to have better access to
maternal health medicines than those in countries with poor quality of health facilities.
Therefore, I reject the null hypothesis and conclude that access to essential maternal health
medicines can be predicted based on the quality of health facilities in a country.
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Research question 4. The Forth question was stated as follows: Can access to essential
maternal health medicines be predicted based on the quality of health services provided in a
country?
Ho4: Access to essential maternal health medicines cannot be predicted based on the
quality of health services provided in a country
Ha4: Access to essential maternal health medicines can be predicted based on the quality
of health services provided in a country.
A chi-square test of independence was performed to examine the relation between quality
of health services and access to essential maternal health medicines. The vast majority (77.9%)
of countries enrolled in the study reported relatively poor quality health services compared to
22.1% with poor quality.
The standardized deviations to measure the magnitude of the difference between
observed and expected values on women’s access to essential maternal health medicines by the
strength of a country’s health system governance (Spiegel, Schiller, and Srinivasan, 2009) was
not significant (< +- 1.95).
Table 8
Standardized Deviations of Quality of Health Services by Access to Maternal Health Medicines

Quality of
Health Services

Strong
Weak

Access to Maternal Health Medicines
Good
Poor
+0.2
-0.5
-0.1
+0.3

The bivariate analysis did not show a statistically significant association between quality
of health services and access to essential maternal health medicines χ (1) = 0.462, OR = 1.389,
CI [ 0.537, 3.598], p = .497. Therefore, I accept the null hypothesis and conclude that women’s
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access to essential maternal health medicines cannot be predicted based on the quality of health
services.
Research question 5. The fifth question was stated as follows: Can access to essential
maternal health medicines be predicted based on the robustness of a country’s health financing?
Ho5: Access to essential maternal health medicines cannot be predicted based on the
robustness of a country’s health financing?
Ha5: Access to essential maternal health medicines can be predicted based on the
robustness of a country’s health financing.
A chi-square test was performed to examine the relation between health care financing
and access to essential maternal health medicines. The vast majority (85.7%) of countries
enrolled in the study had relatively robust health care financing compared to 14.3% with poor
quality.
The standardized deviations to measure the magnitude of the difference between
observed and expected values on women’s access to essential maternal health medicines by the
strength of a country’s health system governance (Spiegel, Schiller, and Srinivasan, 2009)
showed that countries with more robust health financing had a negative deviation towards poor
access to essential maternal health medicines (table 8) than those with less robust health
financing. The reverse was the case for countries with less robust health care financing. A
negative standardized deviation indicates that the observed values are lower than expected and a
positive standardized deviation that the observed values are higher than expected.
More countries (60.0%) with less robust health care financing reported poor access to
essential maternal health medicines compared with those with more robust (12.2%).
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Table 9
Standardized Deviations of Health Care Financing by Access to Maternal Health Medicines

Health
Financing

Robust
Less Robust

Access to Maternal Health Medicines
Good
Poor
+1.0
-2.1
-2.5
+5.1

The bivariate analysis showed a statistically significant association between the
robustness of health care financing and access to essential maternal health medicines χ(2) =
38.068, OR = 10.773, CI [ 4.578, 25.352], p = .000. Women in countries with more robust health
care financing were more likely to have better access to maternal health medicines than those in
countries with less robust health care financing. A multivariate analysis that followed retained
the statistical significant association between the quality of health facilities in a country and
access to essential maternal health medicines (β= -.514, t = - 4.993, CI [ - 0.720, - 0.309], p
<0.001). These findings suggest that women in countries with more robust health financing were
more likely to have better access to maternal health medicines than those in countries with less
robust health financing. Therefore, I reject the null hypothesis and conclude that access to
essential maternal health medicines can be predicted based on robustness of a country’s health
financing.
Research question 6. The Sixth question was stated as follows: Can access to essential
maternal health medicines be predicted based on the strength of data reporting on key maternal
health medicines indicators in a country?
Ho6: Access to essential maternal health medicines cannot be predicted based on the
strength of data reporting on key maternal health medicines indicators in a country
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Ha6: Access to essential maternal health medicines can be predicted based on the
strength of data reporting on key maternal health medicines indicators in a country.
A chi-square test of independence was performed to examine the relation between health
care financing and access to essential maternal health medicines. The vast majority (64.9%) of
countries enrolled in the study had relatively weak reporting for key maternal health medicines
indicators compared to 35.1% with stronger reporting.
The standardized deviations to measure the magnitude of the difference between
observed and expected values on women’s access to essential maternal health medicines by the
strength of a country’s health system governance (Spiegel, Schiller, and Srinivasan, 2009)
showed that countries with stronger reporting had a negative deviation towards poor access to
essential maternal health medicines (table 8) than those with weak reporting. A negative
standardized deviation indicates that the observed values are lower than expected and a positive
standardized deviation that the observed values are higher than expected.
More countries (23.6%) with weak maternal health medicines indicator reporting
mechanisms reported poor access to essential maternal health medicines compared with those
with stronger mechanisms (7.7%).
Table 10
Standardized Deviations of National Reporting of Key Maternal Health Medicine Indicators by
Access to Maternal Health Medicines

National
Reporting of
MH Indicators

Access to Maternal Health Medicines
Good
Poor
+1.0
-2.1

Strong
Reporting
Weak Reporting -0.7

+1.6
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The bivariate analysis showed a statistically significant association between the national
reporting of key maternal health medicine indicators and access to essential maternal health
medicines χ(2) = 8.680, OR = 3.709, CI [ 1.482, 9.282], p = .003. Women in countries with
better reporting of indicators were more likely to have better access to maternal health medicines
than those in countries with weak reporting.
However, a multivariate analysis that followed did not retain the statistically significant
association between national reporting of key maternal health medicine indicators and access to
essential maternal health medicines (β= -.0.047, t = -.394, CI [ -0.281, 0.487], p =.694).
Therefore, I accept the null hypothesis and conclude that access to essential maternal health
medicines cannot be predicted based on national reporting of key maternal health medicine
indicators.
Summary
This study included 12 questions and 6 hypotheses investigating the association between
health system characteristics and women’s access to essential maternal health medicines in 37
low and middle-income countries.
The analysis involved bivariate and multivariate analyses. Bivariate analyses showed that
five of the six health system characteristics examined (strength of health system governance,
strength of medicine procurement, distribution and supply system, quality of health facilities,
robustness of health system financing, and national reporting of key maternal health medicine
indicators) had a statistically significant association with women’s access to essential maternal
health medicines with a p-value < .05. quality of health services had no statistically significant
association with women’s access to essential maternal health medicines p > .05.
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Multivariate analyses included the five independent variables above, which had a p-value
<.05. The second step included a multiple logistic regression analysis to test of the five
independent that had a statistically significant association with the outcome variable and a pvalue < .05. significantly predicted access to essential maternal health medicines. The results of
the regression indicated that three predictors explained 27% of the variance (R2 =.266,
F(5,162)=13.12, p<.01). It was found that the strength of a country’s medicine procurement,
distribution, and supply system significantly predicted access to essential maternal health
medicines (β= -.41, p<.001), as did robustness or health system financing (β= -.51, p<.001), and
quality of health facilities (β= -.34, p<.05).
I conclude that the strength of a country’s medicine procurement, distribution, and supply
system medicines, the robustness of health system financing and quality of health facilities (β= .34, p<.05). significantly predicted access to essential maternal health medicines in low and
middle-income countries.
Chapter 5 includes a discussion of health system characteristics that have shown a
statistically significant association with access to maternal health medicines in 37 low and
middle-income countries and a comparison of these findings with previous studies. It presents
the study limitations, its implications for positive social change, and recommendations for
research, policy and practice.
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Section 4: Application to Professional Practice and Implications for Social Change
Introduction
This study was a quantitative cross-sectional survey using secondary data from the
USAID MCHIP and WHO pharmaceutical 2011/2012 survey. It examined the association
between health system characteristics and women’s access to essential maternal health
medicines. Postpartum hemorrhage (PPH), pre-eclampsia and eclampsia together account for
nearly half (41%) of the 289,000 pregnancy-related deaths worldwide (WHO, et al., 2014).
Access to oxytocin, misoprostol and magnesium sulfate (herein referred to as essential maternal
health medicines) - three medicines that prevent and treat these pregnancy-related complications
(Fujioka, & Smith, 2011), has remained suboptimal, in particular among women in developing
countries (USAID, Landscape Analysis: Postpartum Hemorrhage Solutions, unpublished data,
2012). The suboptimal access to these medicines may explain in part the persisting high maternal
mortality rates in developing countries. This study was conducted to identify the health system
determinants of women’s access to essential maternal health medicines in developing countries.
The data analysis included bivariate and multivariate analyses that showed that the
strength of a country’s medicine procurement, distribution, and supply system, robustness of
health system financing, and quality of health facilities had a statically significant association
with women’s access to maternal health medicines. The findings showed that women in
countries with stronger health system governance AOR = 1.368, 95% CI [ 1.239, 1.150], p < .01;
stronger medicine procurement, distribution and supply system AOR = 3.740, 95% CI [ 1.486,
9.411], p < .05; better quality of health facilities AOR = 3.781, 95% CI [ 1.849, 7.733], p <0.001;
more robust health care financing AOR = 10.773, 95% CI [ 4.578, 25.352], p <0.01; better
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reporting for maternal health medicines indicators AOR = 3.709, 95% CI [ 1.482, 9.282], p
<0.01; were more likely to have better access to maternal health medicines. The quality of health
services, had no statistically significant association with women’s access to maternal health
medicines.
Interpretation of the Findings
Study Findings and Past Research
Strength of health system governance and access to essential maternal health
medicines. The study analysis showed that pregnant women living in countries with stronger
health system governance were more likely to have better access to essential maternal health
medicines. Although more countries (61.7%) recognize access to medicines as a right to health in
their constitution compared with those that had maternal health medicines on their EML (52.8%)
and had treatment guidelines (49.3%), availability of medicines on the EML seemed to be the
only measure with statistically significant relationship with access to medicines (p<0.001).
Observations regarding these three measures indicate a level of political will for reversing high
maternal mortality rate in developing countries. Availability of essential maternal health
medicines in EML also indicate a level of recognition for promoting rational use of essential
maternal health medicines as per WHO recommendations (WHO 2004).
This study supports findings from studies conducted by Ridge et al. (2010), Muldoon et
al (2011), Smith et al., (2014), Tran & Bero (2015). Ridge et al., showed that a critical
component for adequate access to and use of MgSO4 was the inclusion of MgSO4 in National
Essential Medicines List (NEML), the availability of Standard Treatment Guidelines (STG) and
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registration of medicines in the country for use in treatment of severe pre-eclampsia and
eclampsia.
Smith et al., found that countries that reported infrequent availability of misoprostol
indicated a lack of a national policy supporting misoprostol as a principle cause. Similarly, Tran
& Bero found that the first common facilitator of quality use of oxytocin egometrin and
magnesium sulfate at the government policy level was that all three essential medicines were
consistently listed on national EMLs.
Medicines supply system. This study examined the association between the strength of a
country’s medicine supply system and women’s access to essential maternal health medicines.
The results showed, in a bivariate and multivariate analysis, that women in countries that had
stronger medicines supply system had a higher likelihood of having access to essential maternal
health medicines than those with weak medicines supply systems. Descriptive statistics for each
measure of medicine supply system assessed (medicines procurement and medicines
distribution) further showed that more countries had stronger medicines procurement system
than they did medicines distribution systems, and countries with stronger distribution systems
were more likely to have better access than those with stronger procurement systems.
These findings are similar to Hopu, Ranganathan & Dodoo, 2011 assertions that countries
lack essential medicines because of fragile supply systems and poor-quality products. Ridge,
Bero & Hill (2010) found that poor availability of magnesium sulfate in Zambia reflected a
limitation of the countries procurement system. Another similar observation made by Ridge et
al., (2010) study is that procurement was based on presence of medicines in a country’s essential
medicines list, and supply of medicines to health facilities depended on availability of medicines
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in central medical stores – which aligns with findings from this study that found a significant
relationship between medicines distribution systems and access to medicines.
Findings from this study however differed from those of Haddad and Fourniew (1995)
who found that in Zaire, s steady supply of medicines did not reverse a reduction in utilization.
Similarly, Mwabu (1993) found that greater availability of medicines had a negative relationship
with utilization of these medicines. These findings may be attributed to Ridge et al. (2010)
observation that lack of demand by health professionals at the health center level negatively
affected access to essential maternal health medicines.
Quality of health facilities: The study examined the association between the quality of
health facilities in a country and women’s access to essential maternal health medicines.
Observations from the literature suggest that the concept of quality could be a difficult factor to
capture in both cross-sectional and time-series analyses. Hence for the purpose of this study, a
key indicator for quality used included number of hospital beds per 10,000 population. Findings
of bivariate and multivariate analyses showed that women in countries with better quality health
facilities had a higher likelihood of receiving essential maternal health medicines when needed.
Findings from this study aligns with findings from studies carried out by Bitran, 1989,
Yoda, 1989, Hutton, 2004; and James et al., 2006. These studies found that utilization was lower
where quality of care was perceived to be lower. They also found that utilization ins smallerphased -in programs increased when combined with quality improvements. Also, Denton, et al.
(1990) and Akin, et al. (1990) in their study in Nigeria found that facility conditions were
significantly associated with service utilization.
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However, findings from this study differed from those of Chalker (1995), Anis (1981),
Chalker and Anis found that rural health post had reasonable good quality facilities but were not
used. Denton et al., and Akin et al., in the same study mentioned earlier, noted that Machineries
(x-ray machine, and laboratories) were not significantly associated with service utilization.
Quality of health services provided in a country: The study examined the association
between quality of health services and women’s access to maternal health medicines. Nearly half
(45%) of countries reported less comprehensive education and trainings for human resources for
health while a little more than half (59% and 67% respectively) reported relatively less adequate
human resources for health and narrow scope of practice for midwives and birth attendants.
Except for education and training, other indicators for quality of health services showed
statistically significant associations with the outcome variable. However, the association between
the quality of health services and access to maternal health medicines not statistically significant
in bivariate analysis.
These findings agree with findings from seven studies by Anis, (1981), Denton, et al.
(1990) and Akin, et al. (1990), Javadi, and Bigdeli, (n.d) Heller (1982) and Ainstworth et al.,
(1993) Ridge et al. (2010); (Muldoon et al., 2011).
Denton, et al. (1990) and Akin, et al. (1990) findings suggested that number of support
personnel, nurses, and doctors per capita was not significantly associated with service utilization.
Rouse (2008), Javadi, and Bigdeli, (n.d) found that service delivery affected how medicines can
reach patients and the extent to which rational use are upheld. Heller (1982) and Ainstworth et
al., (1993) also found that the association between the probability of being seen by a physician
and service access was insignificant. Nurses, doctors and skilled attendant density were
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associated with decreased mortality for infants (Muldoon et al., 2011). Ridge et al. (2010) found
a lack of in-service training in the use of specific medication as a barrier to access to that
medication.
National health system financing: The study examined the association between the
robustness of a countries health system financing and access to essential maternal health
medicines and found that women in countries with more robust health system financing were
more likely to have better access to these medicines.
This study aligns with Javadi and Bigdeli, (n.d) who found that financing systems are a
major bottle neck to access due to low affordability of medicines. Without national policies to
give universal access to essential maternal health medicines.
Study Findings and Ishikawa (Cause Effect) Model
This study used the Ishikawa (cause effect) model that posits that multiple factors with
dynamic processes influence a given outcome are varying levels. The model has been used to
illustrate the relationship between a given outcome and all the factors that influence this
outcome, and provide additional insight into the behavior of processes (Ishikawa, 1960).
Ridge et al (2010) fishbone diagram advanced that barriers and facilitators to availability
and use of maternal health medicines occur at different levels of a health system including
regulatory, government, supply, procurement, distribution, health facility, and health
professional levels. The 2010 model advanced that certain primary determinants lead to
improved availability and use of essential maternal health medicines.
This study examined health system building blocks as an intervention to improve
availability, affordability and accessibility (access) of essential maternal health medicines (health
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outcomes). Its findings support Ridge et al’s model. They showed that women living in countries
with stronger health system governance, stronger medicine supply system, better quality of
health facilities, more robust health care financing, and better reporting for maternal health
medicines indicators were more likely to find maternal health medicines available, affordable
and accessible when needed.
Further, certain individual characteristics such as presence of medicines in a countries
essential medicines list, midwives scope of practice, and strength of medicines distribution
system played an important role in women’s access to maternal health medicines. In this regard,
Ishikawa cause effect model was a useful model that guided the identification of the study
variables, design of study questions and hypotheses, data analysis, and interpretation of findings.
Limitations of the Study
There were five limitations in this study. First, the study used a cross-sectional
quantitative design with institutional level data collected at one point in time (Sedgwick, 2014).
The cross-sectional quantitative nature of this study did not allow any causal inferences, nor
explanatory dimensions to observations.
Second, different measures of equity and economic status have been considered as
predictors of access in developing countries (Wegstaff, 2000b; Filmer & Pritchett, 2001; Heller,
1982; Dzator et al., 2004). Since this study was not a household survey, data was not collected at
the household or population level. Consequently, the study missed out of demand side factors of
a health system that potentially affect access.
Factors like geographical location, age, hospital waiting time, time spent travelling to
health facility, education or occupation, household consumption and literacy levels are important
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factors that would have provided greater insights into the relationship between demand side
dynamics of a countries health system and access to maternal health medicines. Other important
aspects of health system determinants not covered in this study include aspects of market
dynamics like procurement prices of medicines, monopoly of few pharmaceutical companies and
small markets.
Third, the self-reporting countries were at risk of social desirability bias by giving
socially acceptable answers. Third, the observational nature of the study did not allow any causeand-effect analysis in the absence of variable manipulation. Forth, the cross-sectional nature of
the study did not allow any sequencing of events between independent and dependent variables
nor any trend analysis on the study outcome.
Recommendations for Further Research
This study was the first cross sectional study to examine the health system determinants
of access to maternal health medicines in 37 low and middle-income countries. It has highlighted
the important role of quality of health care facilities, public health financing and data collection
and monitoring of maternal health medicines indicators with access to essential maternal health
medicines. It has also pointed to some knowledge gaps and areas for further research.
The cross-sectional quantitative nature of this study did not allow any causal inferences,
nor explanatory dimensions to observations. A prospective study of access to essential maternal
health medicines can help understand the sequencing of events and establish cause-and-effect
relationships among independent variables. Furthermore, future studies should include other
health system characteristics (independent variables) not measured in this study and should
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include qualitative dimensions to foster more in-depth understanding of the intricate dynamics of
access to maternal health medicines.
The achievement of better access to maternal health medicines for woman in developing
countries will depend on the effectiveness and level of implementation of innovative strategies
specific to the context and realities of each country. Therefore, further studies are needed to
identify the most effective strategies to strengthen health systems in developing countries – in
other to improve women’s access to essential maternal health medicines.
Implications
Implications for Positive Social Change
This study examined an important health issue affecting vulnerable women in developing
countries where health disparities and social injustices are evident through the disproportional
burden of maternal deaths (DHS Program, n.d.). Access to maternal health medicines has
remained suboptimal in many developing countries despite government’s and international
development efforts. Limited understanding of the drivers of access to these medicines in these
countries may have contributed to the persisting inequalities in access to these medicines.
This study will foster positive social change by generating knowledge on the predictors
of access to live-saving maternal health medicines among women in resource-poor settings to
help policy makers, health mangers, and service providers understand not only the barriers to
access faced by this vulnerable population, but the comparative strength of each barrier in
mitigating access to medicines.
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The findings, if used appropriately, could guide the design of public health interventions
aimed at improving access to essential maternal health medicines in resource poor settings, and
reduce the southern - western gap in Maternal health outcomes.
For these reasons, the dissemination of the study findings will target the Ministries of
Public Health, International public health agencies, nongovernmental organizations (NGO’s),
donors and research institutions. Local and international civil society advocates and experts will
also be targeted through program, policy, and strategic meetings and conferences. Besides, the
study will be published in peer-reviewed journals to further share its findings with the
international community.
Implications for Practice
This study may play an important role in the design of interventions to improve
availability, affordability and accessibility of maternal health medicines in developing
countries. Its findings have pointed to three important areas of work: the quality of care,
funding for public health, and data reporting for maternal health medicines indicators. While it
is important to take be holistic in addressing health system barriers to access to medicines,
ministries of health may consider prioritize programs based on their relative potentials to
maximize impact, more so in this era of shrinking resources for public health.
Financing for public health in these countries emerged as the stronger predictor of access
to maternal health medicines. In this era of declining resources for public health, National and
local level maternal health programs may want to consider thinking creatively on avenues to
mobilize resources with the limited resources available. Exploring and establishing partnerships
with the private sector and other individual sponsors may be a strategic direction to go in coming
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years. could use the evidence generated in this study to identify health system factors limiting
access to and use of maternal health medicines, and prioritize programs based on their relative
potentials to maximize impact.
The Ministry of Public Health should establish Maternal health medicines Quality
Improvement programs (MHM-QIP) to ensure that women experience pregnancy related
emergencies receive all the medicines they need for the well-being of the mother-baby pair.
Like many developing countries (Lehmann, Dieleman, & Martineau, 2008), countries
studied in this project suffer from the maldistribution of health professionals, limited scope of
practice for few health professionals available, and inadequate health care facilities Therefore,
the Ministry of Public Health should put in place a human resource policy that encourages the
training and redistribution of roles and scope of practice for midwives and nurses. The efforts of
government and its implementing partners should aim at getting and retaining trained midwives
and nurses in every rural public health facility.
Conclusion
The persisting high maternal mortality in developing countries testifies to the prevailing
social injustice in access to quality maternal health medicines in disadvantaged populations. This
study was the first to examine the comparative relationship between health system characteristics
and women’s access to three essential maternal health medicines across a wide range of
developing countries. Its findings support the hypothesis that health system characteristics, in
particular, health systems financing, procurement systems and quality of health facilities; can
predict women’s access to essential maternal health medicines.
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This new knowledge is useful to guide global health agencies and national health
authorities in design of interventions, in particular, health financing advocacy, quality
improvements in health care facilities and pharmaceutical supply infrastructure and process
improvement. If successfully implemented, these interventions should help close the developed –
developing country gap in maternal health outcomes. Further research is needed to understand
the demand side drivers of poor access to maternal health medicines at household and
institutional levels in developing countries.
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Appendix

Government/Regulatory

Health system

Appendix 1: Variables and Data Source
Domain/Lev
Variable Name
Questionnaire Item
el
Oxytocin on EML for prevention and treatment
of PE/E
Misoprostol on EML for prevention and
Medicines Approved
treatment of PE/E
at National Level
Misoprostol on the EML
MgSO4 is national policy for treatment of PE/E
Diazapern is national policy for PE/E
Standard treatment guideline translated into
Accessibility of
suitable local protocol
Standard Treatment
Guidelines
Recommended treatment in national standard
treatment guideline

Policy Provision for
Active management of
third stage of labor
(AMTSL)

AMTSL is national policy
AMTSL in service delivery guidelines

National good governance policy present?
Good Governance
Access to essential medicines/technologies as
part of the fulfillment of the right to health,
recognized in the constitution or national
legislation?
Pharmaceuti
cal Supply
System

Procurement

Procurement procedure document in place

and Logistics
Medicine supplied to health care facility

Data Sources

2012 NCHIP
Survey database)
NCHIP Survey
NCHIP Survey
NCHIP survey
NCHIP Survey
WHO
pharmaceutical
country profile
data
WHO
pharmaceutical
country profile
data
NCHIP Survey
NCHIP Survey

WHO
pharmaceutical
country profile
data
WHO
pharmaceutical
country profile
data
WHO
pharmaceutical
country profile
data
WHO
pharmaceutical
country profile
data

16

Health Facility

Equipment’s and
Supplies

Education/Training

Equipment and supplies available for diagnosis
of complications and drug storage

WHO
pharmaceutical
country profile
data
Equipment and supplies are available to
WHO
administer medicine
pharmaceutical
country profile
data
Pre-service education curricula include AMTSL NCHIP Survey
Current global management principles for PE/E
included in in-service training courses

NCHIP Survey

AMTSL included in in-service training
curricula

NCHIP Survey

Pre-service education curricula include current
global management principles for PE/E

NCHIP Survey

Students assessed for competency in
performance of AMTSL

NCHIP Survey

Health providers aware medicine is first–line
treatment
Physicians per 10,000 pop

Health Delivery

Human

Number of hospital beds per 10,000

Resources
Nurses and midwives per 10,000 pop

Trained staff available to administer medicine

Midwives authorized to perform manual

WHO
pharmaceutical
country profile
data
WHO
pharmaceutical
country profile
data
WHO
pharmaceutical
country profile
data
WHO
pharmaceutical
country profile
data
NCHIP Survey
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removal of placenta

Health Financing

Midwife/Skilled Birth
Attendant Scope of
practice

Access to MHLSM Medicine

Data
Collection
and
Reporting

NCHIP Survey

Midwives authorized to diagnose severe PE/E
and administer MgSO4

NCHIP Survey

Total health expenditure as % of Gross
Domestic Product

WHO
pharmaceutical
country profile
data
WHO
pharmaceutical
country profile
data
WHO
pharmaceutical
country profile
data

Health Spending
Private health expenditure as % of total health
expenditure (% of total expenditure on health)

Pharmaceutical expenditure as a % of Health
Expenditure (% of total health expenditure)

National Reporting on
Selected Maternal
Health Indicators

AMSTL included in national HMIS
Indicator to monitor severe PE/E included in
national HMIS

Availability of
Oxytocin

Availability of Oxytocin in health facility

Availability
Availability of MgSo4

Availability of
Misoprostol
Stock Out
Accessibilit
y

Midwives authorized to perform AMTSL with
oxytocin

NCHIP Survey
NCHIP Survey

NCHIP Survey

Availability of Oxytocin in regional/central
medical stores
Availability of MgSo4 in health facilities
Availability of MgSO4 in Central Medical
Stores
Availability of Misoprostol in maternity centers

NCHIP Survey

Frequency of oxytocin stock outs
Frequency of MgSO4 stock outs
Misoprostol piloted for home birth

NCHIP Survey
NCHIP Survey
NCHIP Survey

Misoprostol at home birth scaling up

NCHIP Survey

NCHIP Survey
NCHIP Survey
NCHIP Survey

Home Birth
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Affordabilit
y

ANC attendance

Antenatal care or skilled birth attendance)

NCHIP Survey

Cost of Medicines

Medicine is free of Charge to patients in health
facility
Population covered by a public health service or
public health insurance or social health
insurance, or other sickness funds of total
population)

NCHIP Survey
WHO
pharmaceutical
country profile
data

